<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Neurobiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Neurobiol</journal-id>
<journal-title-group>
<journal-title>Molecular Neurobiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-7648</issn>
<issn pub-type="epub">1559-1182</issn>
<publisher>
<publisher-name>Springer US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31960362</article-id>
<article-id pub-id-type="pmc">7170834</article-id>
<article-id pub-id-type="publisher-id">1875</article-id>
<article-id pub-id-type="doi">10.1007/s12035-020-01875-9</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8760-2167</contrib-id>
<name>
<surname>Fone</surname>
<given-names>Kevin C.F.</given-names>
</name>
<address>
<email>kevin.fone@nottingham.ac.uk</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Watson</surname>
<given-names>David J.G.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Billiras</surname>
<given-names>Rodolphe I.</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sicard</surname>
<given-names>Dorothee I.</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dekeyne</surname>
<given-names>Anne</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rivet</surname>
<given-names>Jean-Michel</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gobert</surname>
<given-names>Alain</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Millan</surname>
<given-names>Mark J.</given-names>
</name>
<address>
<email>mark.millan@servier.com</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.4563.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8868</institution-id><institution>School of Life Sciences, Queen’s Medical Centre, </institution><institution>The University of Nottingham, </institution></institution-wrap>Nottingham, NG7 2UH UK </aff>
<aff id="Aff2"><label>2</label>Centre for Therapeutic Innovation-CNS, Institut de Recherche Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>20</day>
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>20</day>
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2020</year>
</pub-date>
<volume>57</volume>
<issue>5</issue>
<fpage>2144</fpage>
<lpage>2166</lpage>
<history>
<date date-type="received">
<day>7</day>
<month>8</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2020</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Frontocortical NMDA receptors are pivotal in regulating cognition and mood, are hypofunctional in schizophrenia, and may contribute to autistic spectrum disorders. Despite extensive interest in agents potentiating activity at the co-agonist glycine modulatory site, few comparative functional studies exist. This study systematically compared the actions of the glycine reuptake inhibitors, sarcosine (40–200 mg/kg) and ORG24598 (0.63–5 mg/kg), the agonists, glycine (40–800 mg/kg), and D-serine (10–160 mg/kg) and the partial agonists, S18841 (2.5 mg/kg s.c.) and D-cycloserine (2.5–40 mg/kg) that all dose-dependently prevented scopolamine disruption of social recognition in adult rats. Over similar dose ranges, they also prevented a delay-induced impairment of novel object recognition (NOR). Glycine reuptake inhibitors specifically elevated glycine but not D-serine levels in rat prefrontal cortical (PFC) microdialysates, while glycine and D-serine markedly increased levels of glycine and D-serine, respectively. D-Cycloserine slightly elevated D-serine levels. Conversely, S18841 exerted no influence on glycine, D-serine, other amino acids, monamines, or acetylcholine. Reversal of NOR deficits by systemic S18841 was prevented by the NMDA receptor antagonist, CPP (20 mg/kg), and the glycine modulatory site antagonist, L701,324 (10 mg/kg). S18841 blocked deficits in NOR following microinjection into the PFC (2.5–10 μg/side) but not the striatum. Finally, in rats socially isolated from weaning (a neurodevelopmental model of schizophrenia), S18841 (2.5 and 10 mg/kg s.c.) reversed impairment of NOR and contextual fear-motivated learning without altering isolation-induced hyperactivity. In conclusion, despite contrasting neurochemical profiles, partial glycine site agonists and glycine reuptake inhibitors exhibit comparable pro-cognitive effects in rats of potential relevance to treatment of schizophrenia and other brain disorders where cognitive performance is impaired.</p>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (10.1007/s12035-020-01875-9) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>NMDA receptor</kwd>
<kwd>Glycine modulatory site</kwd>
<kwd>D-serine</kwd>
<kwd>Cognition</kwd>
<kwd>Social cognition</kwd>
<kwd>Prefrontal cortex</kwd>
<kwd>Schizophrenia</kwd>
<kwd>Microdialysis</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100011725</institution-id>
<institution>Servier</institution>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer Science+Business Media, LLC, part of Springer Nature 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par2">The role of glutamatergic dysfunction in psychiatric disorders is well established, and N-methyl-D-aspartate (NMDA) receptors retain special interest because of their broad cortical and subcortical distribution, localisation on GABAergic interneurons and pyramidal cells, and key role in regulation of neuroplasticity, cognition, epilepsy, mood and motor behaviour. Furthermore, the NMDA channel blocker, ketamine is attracting interest as a fast-acting antidepressant which is metabolised to (2S,6S;2R,6R)-hydroxynorketamine that activates AMPA receptors [<xref ref-type="bibr" rid="CR1">1</xref>] and causes mTOR- and BDNF-dependent increased dendritic arborisation in dopaminergic neurons which may be beneficial to other mood disorders [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Furthermore, agents <italic>promoting</italic> NMDA activity are also of potential use to treat Alzheimer’s disease, Parkinson’s disease, autism spectrum disorders (ASDs), and schizophrenia [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p>
<p id="Par3">Glutamate activation of the NMDA receptor requires concurrent binding of glycine or, predominantly in the PFC, D-serine at the glycine modulatory site [<xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]. Thus, pharmacological modulation of the glycine site has been prioritised to restore hypofunction by direct agonism, inhibition of enzymes regulating serine metabolism or increasing synaptic glycine by inhibition of glycine transporters [<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR12">12</xref>]. Although glycine and D-serine have been extensively characterised, it has proven very hard to generate small molecule, positive modulators of the glycine site. Recently, the partial agonists GLYX-13 (rapastinel) [<xref ref-type="bibr" rid="CR13">13</xref>] and ((2S, 3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-diazaspiro[3,4]octan-2-yl)butanamide) NYX-2925 [<xref ref-type="bibr" rid="CR14">14</xref>] were shown to enhance hippocampal LTP and cognition in rodent paradigms. Although the cyclic imidazolinone, S18841 [<xref ref-type="bibr" rid="CR15">15</xref>], was not developed clinically, this glycine site partial agonist is a very useful ligand for exploitation in parallel with the prototypical partial agonist D-cycloserine to identify the functional roles of the glycine modulatory site and ascertain underlying potentially beneficial therapeutic mechanisms. This approach was supported by the current findings that unlike other agents tested, S18841 did not significantly elevate microdialysate glycine levels making it a particularly informative agent to examine the impact of partial agonism at the glycine site on cognitive function.</p>
<p id="Par4">NMDA receptor hypofunction is strongly implicated in the pathogenesis of schizophrenia [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Moreover, increased levels of the endogenous NMDA receptor antagonists, N-acetylaspartylglutamate (NAAG), and kynurenate, occur in the cortex and hippocampus [<xref ref-type="bibr" rid="CR18">18</xref>] along with decreased plasma D-serine [<xref ref-type="bibr" rid="CR19">19</xref>] but see [<xref ref-type="bibr" rid="CR20">20</xref>] and glycine in schizophrenia, and depletion of the latter correlates with severity of negative symptoms [<xref ref-type="bibr" rid="CR21">21</xref>]. Genetic and functional studies suggest alterations in the rate-limiting enzyme for D-serine synthesis, D-serine racemase, and the major metabolising enzyme D-amino oxidase particularly in the prefrontal cortex (PFC) may contribute to NMDA receptor hypofunction in schizophrenia [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. D-Cycloserine and the tetrapeptide glycine partial agonist, GLIX-13, improve social behaviour in mice models of ASD [<xref ref-type="bibr" rid="CR23">23</xref>] and D-cycloserine alleviated anxiety, social and vocal communication changes in the valproate rat model of ASD [<xref ref-type="bibr" rid="CR24">24</xref>] as well as attenuating stereotype behaviour in 20 young ASD patients [<xref ref-type="bibr" rid="CR25">25</xref>], but there have been few other clinical trials.</p>
<p id="Par5">Over 70 placebo-controlled clinical trials with glycine modulatory site compounds (including glycine, D-serine, D-cycloserine and sodium benzoate) often given as adjuncts to antipsychotics have shown inconsistent and at best modest improvement in negative symptoms or cognitive domains [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Such inconsistent findings could be due to a bell-shaped dose response effect; desensitisation with chronic administration of glycine agonists, or muscarinic actions of antipsychotics preventing any cognitive improvement (as discussed fully later); or variation in the pharmacological effect of glycine agonists, partial agonists and GlyT1 inhibitors used, a possibility investigated herein. In comparison, another recent meta-analysis showed that NMDA modulators (glycine and D-serine) were more effective than amisulpiride, risperidone and olanzepine at reducing negative symptoms in adolescents at clinical high risk for developing psychosis [<xref ref-type="bibr" rid="CR27">27</xref>]. Therefore, such drugs may be of potential use for preventing the transition of ultra-high-risk subjects to full-blown psychosis and schizophrenia [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. They also warrant further investigation as a treatment for ASD, particularly if preclinical evidence could identify unique pharmacological mechanisms associated with any benefit.</p>
<p id="Par6">GlyT1 inhibitors like sarcosine, ORG25935, and bitopertin (RG1678), increase NMDA receptor-dependent hippocampal LTP [<xref ref-type="bibr" rid="CR30">30</xref>] and attenuate PCP-induced hyper-responsiveness to d-amphetamine in rodent models [<xref ref-type="bibr" rid="CR30">30</xref>]. A few studies have also shown the impact of GlyT1 inhibitors on behaviour in animal models for psychiatric disorders. The GlyT1 inhibitor, ALX-5407, increased prepulse inhibition of acoustic startle (PPI) in DAB/2 mice with naturally low PPI [<xref ref-type="bibr" rid="CR31">31</xref>], ASP2535 reversed a neonatal phencyclidine-induced impairment of NOR [<xref ref-type="bibr" rid="CR32">32</xref>], and ORG25935 reversed the attention deficit seen in the 5-choice continuous performance task in a transcription factor specificity protein 4 hypomorphic mouse model for bipolar disorder and schizophrenia [<xref ref-type="bibr" rid="CR33">33</xref>]. Further, bitopertin showed initial promise against negative symptoms in phase II trials [<xref ref-type="bibr" rid="CR34">34</xref>]. Although phase II/III clinical studies were disappointing [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], recent add-on trials of the D-amino acid oxidase inhibitor, sodium benzoate with the GlyT1 inhibitor, sarcosine, improved cognitive and global functioning in patients with schizophrenia [<xref ref-type="bibr" rid="CR12">12</xref>], so clinical evaluation of drugs that reinforce NMDA receptor activity remains of interest. The current study was therefore performed to determine the key cortical neurotransmitters involved in the cognitive effects of agents that modify glycine function. This should, in turn, help identify reasons underlying the poor predictive translational value of animal models for clinical trials in schizophrenia and help identify potential new therapeutic targets to overcome cognitive and social dysfunction in schizophrenia and other CNS disorders such as ASD.</p>
<p id="Par7">As discussed above, few studies have compared the utility of glycine site direct agonists, partial agonists, and GlyT1 inhibitors, in relevant rodent models to clarify the potential clinical utility of these mechanisms and novel agents to treat schizophrenia. Accordingly, we compared the glycine modulatory site agonists (glycine, D-serine, D-cycloserine and S18841) and GlyT1 inhibitors (sarcosine and ORG25935) on microdialysis levels of glycine and D-serine and other neurotransmitters thought to regulate cognition in the prefrontal cortex (PFC) of rats [<xref ref-type="bibr" rid="CR37">37</xref>]. These compounds were also compared in three cognitive tasks: social recognition, novel object recognition (NOR) and an associative conditioned freezing response (CFR) task (selected for translational relevance to schizophrenia from consensus reviews [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>], and whose predictive validity will be considered in the discussion). In addition, we employed a microinjection procedure to examine the role of the PFC in the action of S18841.</p>
<p id="Par8">Finally, we examined the effect of S18841 in a neurodevelopmental model, rearing rats in social isolation from weaning, that produces behavioural and neurochemical changes resembling schizophrenia [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>] including reduced PFC volume [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>] and hippocampal expression of genes involved in glutamate, GABA and dopamine neurotransmission [<xref ref-type="bibr" rid="CR44">44</xref>]. This model is associated with an impairment in NOR [<xref ref-type="bibr" rid="CR44">44</xref>–<xref ref-type="bibr" rid="CR47">47</xref>], CFR [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR48">48</xref>] and social interaction [<xref ref-type="bibr" rid="CR49">49</xref>], making it ideal for the current investigation.</p>
</sec>
<sec id="Sec2">
<title>Materials and Methods</title>
<sec id="Sec3">
<title>Animals</title>
<p id="Par9">Male Lister hooded rats (Charles River UK) were used for the novel object recognition (NOR) and isolation studies, while male Wistar rats (Charles River L’Arbresle, France) were used for the social recognition and microdialysis studies. All rats were housed in conventional open top cages with food and water available ad libitum under 12 h light/dark cycle (lights on 07.00 h) and constant temperature 21 ± 2 °C and humidity 55 ± 10%. All behavioural studies were performed between 08.00 and 16.00 h, and following every test, the apparatus was thoroughly cleaned with 20% <italic>v</italic>/<italic>v</italic> ethanol and dried to remove odour cues. All studies were performed using a blind protocol, so that the observer was unaware of drug treatment. Experiments were conducted in accordance with the Animals (Scientific Procedures) Act, 1986 and ARRIVE guidelines with approval of University of Nottingham Local Ethical Committee (behaviour) or EU guidelines (microdialysis). All efforts were made to minimise animal suffering, and the number of animals used.</p>
</sec>
<sec id="Sec4">
<title>Extracellular Amino Acids Levels by Microdialysis</title>
<p id="Par10">Male Wistar rats (225–300 g) supplied by Charles River (L’Arbresle, France) were housed in groups (3–4) with free access to food and water. Rats were anaesthetised under chloral hydrate (400 mg/kg, i.p.) and a guide cannula implanted above the PFC at coordinates: AP + 2.2, L ± 0.6 and DV − 0.2. [<xref ref-type="bibr" rid="CR50">50</xref>]. Five days later, a cuprophane CMA/11 probe (4 mm) was implanted and perfused at 1 μl/min with a Ringer solution (NaCl 147.2 mM; KCl 4 mM and CaCl<sub>2</sub> 2.3 mM buffered with phosphate at pH, 7.3) for 150 min to obtain stable baseline levels, and samples taken every 20 min thereafter for 3 h. Amino acid levels were measured in 5 μl dialysate using fluorimetric detection (ex 420 nm; em: 490 nm, FP2020plus, Jasco, Bouguenais, France) after separation by linear gradient chromatography (0% B to 40% B over 40 min where the mobile phase was ammonium acetate (50 mM, pH = 6.8, plus tetrahydrofurane (3%), and B was ammonium acetate (50 mM, pH = 6.8) plus acetonitrile (60%)) using a reverse phase column (Kromasil C18, 250 mm × 2.1 mm, particle size, 5 μm, Cluzeau Info Labo, Courbevoie, France) maintained at 44 °C and a flow rate of 0.4 ml/min as detailed elsewhere [<xref ref-type="bibr" rid="CR51">51</xref>]. At the end of the experiment, sky blue was perfused through the probe and rats killed by pentobarbital overdose to verify correct probe placement by histology in 50 μm sections. Amino acid levels in fractional samples were expressed as a percentage of the mean value during 90 min baseline measurement immediately before treatment.</p>
</sec>
<sec id="Sec5">
<title>Social Recognition</title>
<p id="Par11">Social recognition, a cortical-dependent working memory task based on olfactory discrimination of a novel from a familiar juvenile rat, considered relevant to dysfunction seen in psychiatric disorders [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>], was examined in adult rats. The procedure, described elsewhere [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>], evaluated the promnesic actions of compounds on a scopolamine-induced (1.25 mg/kg s.c.) deficit. Adult male Wistar rats were individually housed for 2 days before testing. On the test day, a juvenile was placed into the home cage for a 5 min session. A second 5 min session was performed immediately after the first one with the same juvenile reintroduced (for evaluation of the promnesic actions of ligands on a scopolamine-induced (1.25 mg/kg s.c.) deficit of recognition). The time (s) spent in active social investigation (i.e., the time spent by adult rat in sniffing, following, biting, jumping and crawling over or under the juvenile) during the first (T1) and the second (T2) session was monitored. The difference “T2–T1” was calculated and dose-response curves produced.</p>
</sec>
<sec id="Sec6">
<title>Social Isolation</title>
<p id="Par12">The social isolation paradigm extensively validated in our laboratory [<xref ref-type="bibr" rid="CR44">44</xref>–<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR56">56</xref>] produces a robust, reproducible behavioural syndrome including phenotype changes relevant to neurodevelopmental disorders with deficits in social behaviour and cognition such as schizophrenia, many of which are reversed by treatment with existing antipsychotics [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. The ability of acute injection of S18841 to reverse deficits in motor and cognitive behaviour was examined in this neurodevelopmental model. Rats were weaned at postnatal day (PND) 24, and half of each litter were housed either in social groups (3–4 per cage, 50 × 33 × 26 cm) or alone (41 × 24 × 20 cm) for the rest of the study. Isolated rats were housed in the same holding room having auditory and olfactory contact but no physical interaction with conspecifics. Rats were isolated for 5 weeks before undergoing a battery of behavioural tasks, arranged in order of least to most aversive (to minimise any sequential effect on subsequent tasks) at approximately 1-week intervals.</p>
</sec>
<sec id="Sec7">
<title>Locomotor Activity</title>
<p id="Par13">Locomotor activity (ambulation and rearing) was measured using infrared beams during a 1 h period as described before and in detail in the <xref ref-type="media" rid="MOESM1">supplementary information</xref> [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR57">57</xref>].</p>
</sec>
<sec id="Sec8">
<title>Novel Object Recognition</title>
<p id="Par14">NOR is a visual learning and memory task that relies on innate preference of rats for novelty. It does not require previous training or re-enforcement [<xref ref-type="bibr" rid="CR58">58</xref>] and is considered to have ethological relevance to human declarative memory [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR59">59</xref>] impaired in schizophrenia. Furthermore, a recent translational study showed that the NOR discrimination ratio obtained in rat studies is a valid analogue of the sensitivity of human recognition memory in a visual-paired comparison task [<xref ref-type="bibr" rid="CR60">60</xref>]. A 4 h inter-trial interval (ITI) prevents rats’ ability to discriminate the novel from familiar object in our two-trial NOR task [<xref ref-type="bibr" rid="CR61">61</xref>] that has been thoroughly validated. Acute treatment with dopamine D<sub>3</sub> receptor antagonists, 5-HT<sub>6</sub> antagonists and mGluR<sub>2/3</sub> agonists reverse this impairment, while D<sub>2</sub> receptor antagonists impair performance using a short ITI [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>], making it ideal choice to evaluate the effect of S14481. During the social isolation rearing study, a 2 h ITI was used with which group-housed vehicle-treated rats readily discriminate the novel from the familiar object [<xref ref-type="bibr" rid="CR57">57</xref>]. In studies investigating the effect of drugs on a delay-induced impairment of NOR, a 4 h ITI was utilised so that normal, adult group-housed vehicle-treated rats were unable to discriminate the novel from the familiar object [<xref ref-type="bibr" rid="CR54">54</xref>]. Twenty-four hours before the test, rats were habituated to the arena (see “<xref ref-type="sec" rid="Sec7">Locomotor Activity</xref>” for details) for 1 h. On the test day, rats were briefly reacclimatized to the arena for 3 min before being returned to the home cage for 1 min. During the familiarisation trial, two identical objects (plastic bottles, 8 cm high and 5 cm diameter, covered in white masking tape) were placed in opposite corners of the arena (5 cm from the side and 10 cm from the end wall). The rat was returned to the arena for 3 min, and exploration of each identical objects was recorded with stopwatches. After a 2 or 4 h ITI (in the social isolation and dose-response studies, respectively), the rat was returned to the arena with one familiar and one novel object (bottle wrapped with 4 black stripes 1.2 cm in width). During this second, choice, trial exploration of each object was recorded for 3 min. Exploratory behaviour was defined as sniffing, licking, touching and direct attention to the object with active vibrissae while the nose is within 1 cm of the object. Climbing on or chewing the object was not considered as exploration. Object exploration time during the choice trial was used to determine the discrimination ratio (time at novel–time at familiar/total choice trial object exploration).</p>
</sec>
<sec id="Sec9">
<title>Conditioned Freezing Response</title>
<p id="Par15">CFR is a well-characterised, species conserved, hippocampal, amygdala and cortical dependent learning and memory task [<xref ref-type="bibr" rid="CR63">63</xref>] utilised to index long-term associative memory of emotional based preference that is impaired in schizophrenia [<xref ref-type="bibr" rid="CR64">64</xref>]. CFR is classically considered as part of the exemplary paradigms to investigate acute threat within the negative valence domain under the RDoC framework. However, the memory component of this paradigm, as investigated in this study, is clearly part of the cognitive system domain of the RDoC matrix highly pertinent to emotional memory and deficits thereof are seen in ASD and schizophrenia [<xref ref-type="bibr" rid="CR65">65</xref>]. CFR was performed in a two-chamber shuttle box with light and dark sides (27 × 25 × 25 cm), separated by an automated door (8 × 8 cm) and a wire grid floor (PanLab, Slab, Barcelona, Spain) using a 3 day test protocol described previously [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. On the first (conditioning) day, rats received S18841 (2.5 or 10 mg/kg) or vehicle (1 ml/kg s.c.) 30 min before being placed in the light side of the chamber. The door opened after 30 s and latency to cross into the dark side was recorded using a floor sensor which closed the door (ShutAvoid, software v.1.8.2., Panlab S.L, USA). After 30 s in the dark side, a 5 s conditioning stimulus (CS, light and 3 kHz, 89 dB tone) was followed by the unconditioned stimulus (US, 1 s 0.4 mA footshock during the last second of the CS) through the grid floor. A further two CS/US were delivered at 55 s intervals. Time spent freezing (completely immobile except for respiration in a hunched posture with inactive vibrissae) between shocks was recorded by stopwatch. Twenty-four and 48 h post-conditioning, rats were returned to the dark side for 300 s without CS/US and time spent freezing recorded again as an index of associative learning and memory. During the extinction trial (48 h post-conditioning), the CS alone was presented after 300 s and freezing recorded for a further 300 s. Behaviour was also recorded through a camera in the roof of the CFR chamber using Ethovision (Noldus) to enable re-assessment if required.</p>
</sec>
<sec id="Sec10">
<title>Microinjection for NOR</title>
<p id="Par16">In order to ascertain the importance of glycine receptors in the prefrontal cortex (PFC) in the cognitive effects of S14481, it was delivered by microinjection into this area. The PFC was selected because of the microdialysis data showing changes in either serine or glycine overflow occurred therein with administration of all the glycine agonists, partial agonists and reuptake inhibitors used herein. Lister hooded rats were anaesthetised with isoflurane (3.5% induction and maintained with 2% in 33% O<sub>2</sub> and 66% N<sub>2</sub>O), placed in a stereotaxic frame to implant cannulae as described before [<xref ref-type="bibr" rid="CR54">54</xref>]. Two 22-gauge guide cannulae, 1.5 mm apart projecting 3.5 mm, were implanted above the PFC or in separate rats 5.0 mm apart projecting 5.0 mm above the striatum (Plastics One) at the following coordinates from bregma: PFC; AP + 3.0, L ± 0.7, DV − 2.3 and striatum; AP + 0.5, L ± 2.5, DV − 4.0 [<xref ref-type="bibr" rid="CR50">50</xref>]. Stylets (Plastics One) placed in the cannulae prevented occlusion. Rats were housed individually and allowed to recover for at least 1 week and handled daily to minimise stress associated with drug infusion. On the test day, rats were lightly restrained, stylets removed and sterile 28-gauge injectors (Plastics One) used to bilaterally infuse 1 μl drug or vehicle over 2 min with an infusion pump (Harvard Apparatus, Holliston, MA), 5 min before the NOR familiarisation trial. After behavioural testing, brains were removed and stored in paraformaldehyde for histological verification of the injection from coronal brain sections according to Paxinos and Watson [<xref ref-type="bibr" rid="CR50">50</xref>].</p>
</sec>
</sec>
<sec id="Sec11">
<title>Materials</title>
<p id="Par17">S18841 (3-Hydroxy-4-imidazolidinone), glycine, D-serine, D-cycloserine, sarcosine and ORG24598 were dissolved in 0.9% (<italic>w</italic>/<italic>v</italic>) saline, pH normalized where appropriate and injected in a volume of 1 ml/kg s.c. 30 min prior to each task except for glycine which was dosed at a volume of 4 ml/kg. L701,324 (7-chloro-4-hydroxy-3-(3-phenoxy) phenyl-2(H)-quinolinone, 5 mg/kg in 4 ml/kg) was suspended in distilled water with a few drops of Tween 80. CPP (3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid, 10 mg/kg in 1 ml/kg) was dissolved in 0.9% (<italic>w</italic>/<italic>v</italic>) saline and pH normalised with NaOH. L701,324 and CPP were injected i.p. 45 min prior to the NOR task. For microinjection into the PFC or striatum, S18841 was dissolved in artificial cerebrospinal fluid (aCSF) containing 10% <italic>w</italic>/<italic>v</italic> hydroxypropyl-β-cyclodextrin. The rat was lightly restrained and vehicle (1 μl/side) or S18841 injected at a rate of 0.5 μl/min 5 min prior to the behavioural analysis.</p>
<sec id="Sec12">
<title>Statistical Analysis</title>
<p id="Par18">In the social recognition task, the difference “T2–T1” was calculated and dose-response curves for promnesic properties analysed by one-way ANOVA followed by Dunnett’s test. The time course of locomotor activity and rears and time spent exploring each object during the NOR choice trial were analysed using two-way repeated measures RM-ANOVA. Total activity counts and object exploration and discrimination ratio during NOR were analysed with two-way ANOVA (but one-way ANOVA for delay-induced NOR impairment studies). Following ANOVA (<italic>P &lt;</italic> 0.05 was considered significant in all cases), Fishers LSD or Dunnett’s tests were used for post hoc analyses. All statistical analyses were performed using GraphPad Prism v7.0 for Windows (GraphPad Software, San Diego, CA, USA) and SPSS (IBM SPSS Statistics v21, USA), and all data shown are mean ± SEM. For microdialysis, time-course effects of drugs on amino acid levels was analysed by two-way ANOVA, with treatment as a between-subjects factor and time a repeated measure, followed by Dunnett’s post hoc tests. Dose effects of drugs were evaluated by comparing the area under the curve during the first 180 min after i.p. injection of the drug or vehicle and statistical analysis was carried out by a two-way ANOVA followed by Bonferroni’s post hoc tests.</p>
</sec>
</sec>
<sec id="Sec13">
<title>Results</title>
<sec id="Sec14">
<title>Effect of Glycine Modulatory Drugs on PFC Dialysate Levels of Amino Acids and Monoamines in Freely Moving Rats</title>
<p id="Par19">Given the pivotal role of PFC function in the modulation of working memory and the cognitive deficits seen in common psychiatric disorders, we used microdialysis to ascertain any common mode of action of the glycine-modifying drugs on neurotransmitter release therein. In freely moving rats, compared to vehicle, both glycine (<italic>F</italic><sub>(1,19)</sub> = 306.7, <italic>P &lt;</italic> 0.001) and the two GlyT1 inhibitors (sarcosine <italic>F</italic><sub>(1,18)</sub> = 710.3, <italic>P &lt;</italic> 0.0001; and ORG24598, <italic>F</italic><sub>(1,29)</sub> = 38.62, <italic>P &lt;</italic> 0.001) significantly increased (by 700, 150 and 130% above basal) glycine in PFC dialysates which peaked at 20 to 40 min (Fig. <xref ref-type="fig" rid="Fig1">1</xref> a and c). In contrast, glycine levels were unaffected by the glycine site agonists, D-serine or D-cycloserine or by S18841. D-serine (<italic>F</italic><sub>(1,9)</sub> = 10.00, <italic>P</italic> = 0.0115) and D-cycloserine (<italic>F</italic><sub>(1,10)</sub> = 42.99, <italic>P &lt;</italic> 0.001) were the only compounds to significantly elevate PFC D-serine levels (Fig. <xref ref-type="fig" rid="Fig1">1</xref> b and d). No compound changed dialysate levels of glutamate, GABA, 5-HT or acetylcholine and only glycine and sarcosine elevated dopamine while glycine also elevated levels of noradrenaline (Table <xref ref-type="table" rid="Tab1">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Effect of glycine modulatory site agonists and glycine transport inhibitors on extracellular glycine (<bold>a</bold> and <bold>c</bold>) and D-serine (<bold>b</bold> and <bold>d</bold>) levels in the prefrontal cortex of freely moving male Wistar rats. Microdialysis samples were taken for 180 min at 20-min intervals following acute systemic injection of S18841, D-cycloserine, ORG 24598, D-serine (all s.c.), glycine and sarcosine (both i.p.). Data is expressed as percentage change from a 40-min baseline taken prior to injection (mean ± SEM, <italic>n</italic> = 5–26). Basal levels of glycine and D-serine were 8.28 ± 1.07 and 0.90 ± 0.13 μM, respectively. Two-way ANOVA for <bold>a</bold>, <bold>b</bold> and <bold>c</bold> (not <bold>d</bold>) showed significant main effects of drug (<italic>P</italic> = 0.001), time (<italic>P</italic> = 0.001) and an interaction (<italic>P</italic> = 0.001). Significant two-way ANOVA was found in <bold>a</bold>: (effect on glycine levels) for ORG 24598: main effect of time (<italic>P &lt;</italic> 0.001) and drug (<italic>P &lt;</italic> 0.001) and interaction (<italic>P &lt;</italic> 0.001); in <bold>b</bold>: (effect on D-serine levels) for D-cycloserine: main effect of time (<italic>P &lt;</italic> 0.001), drug (<italic>P &lt;</italic> 0.001) and interaction (<italic>P &lt;</italic> 0.001) and D-serine: main effect of time (<italic>P &lt;</italic> 0.001), drug (<italic>P &lt;</italic> 0.001) and interaction (<italic>P &lt;</italic> 0.001); and in <bold>c</bold>: (effect on glycine) for glycine: main effect of time (<italic>P &lt;</italic> 0.001), drug (<italic>P &lt;</italic> 0.001) and interaction (<italic>P &lt;</italic> 0.001) and sarcosine: main effect of time (<italic>P &lt;</italic> 0.001), drug (<italic>P &lt;</italic> 0.001) and interaction (<italic>P &lt;</italic> 0.001). *<italic>P &lt;</italic> 0.001, **<italic>P &lt;</italic> 0.01, ***<italic>P &lt;</italic> 0.001 between drug and vehicle at that time, Bonferroni’s multiple comparisons post hoc test</p></caption><graphic id="MO1" xlink:href="12035_2020_1875_Fig1_HTML"></graphic></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Effect of pharmacological agent on microdialysis amino acid and neurotransmitter levels in the prefrontal cortex of conscious rats. Data (mean <underline>+</underline> SEM (<italic>n</italic>)) for vehicle and drugs presented as area under the curve expressed as % min/1000; basal values of amino acids are given in μM while those for NE, DA, 5-HT and ACh are in nM. Doses are mg/kg. Significant changes in italic font, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001 from the vehicle-treated control administered by the same injection route. GlyT1 I, glycine transporter-1 inhibitor; agonist, partial agonist and antagonist refer to the activity at the glycine modulatory site</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Drug (dose, route)</th><th>Activity</th><th>Glycine</th><th>D-Serine</th><th>L-Serine</th><th>Glutamate</th><th>GABA</th><th>NE</th><th>DA</th><th>5-HT</th><th>ACh</th></tr></thead><tbody><tr><td><italic>Basal (μM)</italic></td><td></td><td><italic>8.28 ± 1.07</italic></td><td><italic>0.90 ± 0.13</italic></td><td><italic>12.62 ± 0.13</italic></td><td><italic>1.77 ± 0.26</italic></td><td><italic>0.06 ± 0.01</italic></td><td><italic>0.43 ± 0.06</italic></td><td><italic>0.39 ± 0.03</italic></td><td><italic>0.23 ± 0.02</italic></td><td><italic>0.75 ± 0.13</italic></td></tr><tr><td>Vehicle (s.c.)</td><td>Control</td><td>16.54 ± 0.55 (26)</td><td>17.53 ± 0.49 (6)</td><td>18.18 ± 0.28 (6)</td><td>16.51 ± 0.52 (18)</td><td>16.65 ± 0.66 (23)</td><td>20.6 ± 1.4 (11)</td><td>18.1 ± 0.6 (13)</td><td>16.7 ± 0.5 (6)</td><td>19.1 ± 0.9 (8)</td></tr><tr><td>Vehicle (i.p.)</td><td>Control</td><td>17.29 ± 0.17 (15)</td><td>17.71 ± 0.21 (6)</td><td>17.43 ± 0.26 (6)</td><td>16.15 ± 0.47 (12)</td><td>15.52 ± 0.68 (13)</td><td>19.7 ± 0.6 (11)</td><td>18.1 ± 0.6 (11)</td><td>16.9 ± 0.7 (11)</td><td>17.8 ± 1.6 (10)</td></tr><tr><td>S18841 (2.5 s.c.)</td><td>Partial agonist</td><td>16.15 ± 0.48 (8)</td><td>17.78 ± 0.31 (4)</td><td>17.98 ± 1.48 (4)</td><td>17.40 ± 0.83 (8)</td><td>13.96 ± 1.06 (8)</td><td>18.9 ± 1.1 (6)</td><td>18.5 ± 1.1 (6)</td><td>15.2 ± 0.3 (6)</td><td>20.5 ± 1.1 (7)</td></tr><tr><td>D-Cycloserine (40 s.c.)</td><td>Partial agonist</td><td>18.29 ± 0.60 (6)</td><td><italic>30.29 ± 1.23 (6)***</italic></td><td>19.33 ± 0.43 (6)</td><td>18.00 ± 1.15 (6)</td><td>17.24 ± 1.41 (6)</td><td>19.4 ± 0.8 (6)</td><td>19.1 ± 0.7 (5)</td><td>16.7 ± 2.2 (4)</td><td>–</td></tr><tr><td>D-Serine (160 s.c.)</td><td>Agonist</td><td>17.06 ± 0.50 (6)</td><td><italic>571.12 ± 131.79 (5)***</italic></td><td>17.84 ± 0.39 (7)</td><td>16.50 ± 0.87 (6)</td><td>16.79 ± 1.39 (6)</td><td>21.2 ± 1.3 (4)</td><td>20.3 ± 0.5 (4)</td><td>18.1 ± 2.3 (4)</td><td>18.1 ± 3.2 (4)</td></tr><tr><td>Glycine (200 i.p.)</td><td>Agonist</td><td><italic>45.02 ± 2.64 (6)***</italic></td><td>16.47 ± 0.52 (5)</td><td>20.06 ± 0.30 (9)</td><td>14.53 ± 0.85 (6)</td><td>17.49 ± 1.68 (6)</td><td><italic>25.3 ± 1.7 (8)*</italic></td><td><italic>25.7 ± 2.4 (8)*</italic></td><td>17.1 ± 1.3 (6)</td><td>23.0 ± 1.7 (6)</td></tr><tr><td>ORG 24598 (2.5 s.c.)</td><td>GlyT1 I</td><td><italic>22.03 ± 0.48 (5)***</italic></td><td>17.81 ± 0.59 (5)</td><td>17.37 ± 0.50 (5)</td><td>16.87 ± 0.30 (5)</td><td>18.16 ± 1.48 (5)</td><td>20.4 ± 1.2 (5)</td><td>20.0 ± 1.7 (5)</td><td>17.9 ± 2.2 (4)</td><td>21.0 ± 1.3 (6)</td></tr><tr><td>Sarcosine (200 i.p.)</td><td>GlyT1 I</td><td><italic>23.07 ± 0.42 (5)**</italic></td><td>19.51 ± 0.84 (6)</td><td>21.24 ± 0.43 (6)</td><td>17.86 ± 0.34 (5)</td><td>18.56 ± 1.21 (5)</td><td></td><td></td><td></td><td></td></tr><tr><td>Sarcosine (800 i.p.)</td><td>GlyT1 I</td><td align="char" char="×"><italic>28.90 ± 2.30 (5)*</italic></td><td>18.6 ± 0.5 (5)</td><td><italic>24.5 ± 0.9 (5)*</italic></td><td>16.0 ± 1.0 (5)</td><td>18.6 ± 1.0 (5)</td><td>21.8 ± 0.9 (8)</td><td><italic>22.3 ± 1.7 (8)*</italic></td><td>16.7 ± 0.9 (8)</td><td>20.8 ± 2.6 (3)</td></tr><tr><td>L701,324 (10 i.p.)</td><td>Antagonist</td><td>16.14 ± 0.25 (4)</td><td>17.87 ± 0.24 (4)</td><td>16.80 ± 0.12 (4)</td><td>15.29 ± 0.29 (4)</td><td>16.17 ± 0.21 (4)</td><td>22.5 ± 2.4 (5)</td><td>22.7 ± 2.0 (5)</td><td>18.8 ± 1.8 (5)</td><td>20.0 ± 1.6 (10)</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="Sec15">
<title>Effect of Glycine Modulatory Drugs on Disruption of Social Recognition by Scopolamine</title>
<p id="Par20">We next compared the ability of all the glycine-modifying drugs to reverse a cholinergic-induced impairment of social discrimination of a novel from a familiar juvenile rat, a cortical-dependent working memory task to examine the functional consequence of the microdialysis data in adult rats. Social recognition was selected because of its perceived translational relevance to dysfunction in psychiatric disorders [<xref ref-type="bibr" rid="CR53">53</xref>]. In the social recognition task with no intertrial delay, vehicle rats investigated the juvenile rat significantly less in T2 than T1, demonstrating social recognition memory (Fig. <xref ref-type="fig" rid="Fig2">2</xref>). However, adults given scopolamine (1.25 mg/kg s.c.) prior to T1 spent a similar time investigating the juvenile in T2 and T1, indicative of impaired recognition memory compared to vehicle controls. The glycine site agonists, glycine (Fig. <xref ref-type="fig" rid="Fig2">2a</xref>, main effect of scopolamine, <italic>F</italic><sub>(1,50)</sub> = 53.14, <italic>P &lt;</italic> 0.001; glycine, <italic>F</italic><sub>(3,50)</sub> = 3.93, <italic>P</italic> = 0.0135 and an interaction, <italic>F</italic><sub>(3,50)</sub> = 3.73, <italic>P</italic> = 0.0170), D-serine (Fig. <xref ref-type="fig" rid="Fig2">2b</xref>, scopolamine, <italic>F</italic><sub>(1,52)</sub> = 24.32, <italic>P &lt;</italic> 0.0001; D-serine, <italic>F</italic><sub>(3,52)</sub> = 2.57, <italic>P</italic> = 0.0644 and interaction, <italic>F</italic><sub>(3,52)</sub> = 2.66, <italic>P</italic> = 0.045), D-cycloserine (Fig. <xref ref-type="fig" rid="Fig2">2c</xref>, scopolamine, <italic>F</italic><sub>(1,51)</sub> = 31.59, <italic>P &lt;</italic> 0.0001; D-cycloserine, <italic>F</italic><sub>(3,51)</sub> = 5.93, <italic>P</italic> = 0.0015 and interaction, <italic>F</italic><sub>(3,51)</sub> = 7.22, <italic>P</italic> = 0.0004), and S18841 (Fig. <xref ref-type="fig" rid="Fig2">2f</xref>, scopolamine, F<sub>(1,581)</sub> = 69.92, <italic>P &lt;</italic> 0.0001; S18841, <italic>F</italic><sub>(5,81)</sub> = 7.76, <italic>P &lt;</italic> 0.0001 and interaction, <italic>F</italic><sub>(5,81)</sub> = 6.85, <italic>P &lt;</italic> 0.0001) and the GlyT1 inhibitors, sarcosine (Fig. <xref ref-type="fig" rid="Fig2">2d</xref>, scopolamine, <italic>F</italic><sub>(1,61)</sub> = 21.55, <italic>P &lt;</italic> 0.0001; sarcosine, <italic>F</italic><sub>(4,61)</sub> = 2.94, <italic>P</italic> = 0.0274 and interaction, <italic>F</italic><sub>(4,61)</sub> = 6.90, <italic>P</italic> = 0.0001) and ORG24598 (Fig. <xref ref-type="fig" rid="Fig2">2e</xref>, scopolamine, <italic>F</italic><sub>(1,62)</sub> = 45.08, <italic>P &lt;</italic> 0.0001; ORG24598, <italic>F</italic><sub>(4,62)</sub> = 6.48, <italic>P</italic> = 0.0002 and interaction, <italic>F</italic><sub>(4,62)</sub> = 7.76, <italic>P &lt;</italic> 0.0001) all reversed the impairment in social recognition caused by scopolamine, restoring the reduction in time spent exploring the juvenile in T2. Of particular note for every compound, the lowest dose to significantly increase social discrimination was lower than or equal to that shown to elevate glycine or D-serine levels in PFC microdialysates (Table <xref ref-type="table" rid="Tab2">2</xref>). Furthermore, reversal of the recognition impairment occurred irrespective of whether the drug elevated glycine or D-serine, suggesting that either mechanism was effective, as is partial agonism at the glycine site.<fig id="Fig2"><label>Fig. 2</label><caption><p>Reversal of a scopolamine-induced deficit in social recognition in Wistar rats by <bold>a</bold> glycine, <bold>b</bold> D-serine, <bold>c</bold> D-cycloserine, <bold>d</bold> sarcosine, <bold>e</bold> ORG 24598 and <bold>f</bold> S18841. Data shown (T2-T1) is the time difference (s) in the exploration by the adult of the juvenile rat between the second (T2) and first (T1) trials. Values are means ± SEM, <italic>n</italic> = 5–13. Rats were sequentially administered test drug (at doses indicated, s.c.) or vehicle (0.9% (<italic>w</italic>/<italic>v</italic>) saline, 1 ml/kg) 30 min prior to T1. Two-way ANOVA showed <bold>a</bold> for glycine: main effect of scopolamine (<italic>P &lt;</italic> 0.001), glycine (<italic>P</italic> = 0.0135) and an interaction (<italic>P</italic> = 0.0170); <bold>b</bold> D-serine: main effect of scopolamine (<italic>P &lt;</italic> 0.0001), D-serine (<italic>P</italic> = 0.0644) and interaction (<italic>P</italic> = 0.045); <bold>c</bold> D-cycloserine: main effect of scopolamine (<italic>P &lt;</italic> 0.0001), D-cycloserine (<italic>P</italic> = 0.0015) and interaction (<italic>P</italic> = 0.0004); <bold>d</bold> sarcosine: main effect of scopolamine (<italic>P &lt;</italic> 0.0001), sarcosine (<italic>P</italic> = 0.0274) and interaction (<italic>P</italic> = 0.0001); <bold>e</bold> ORG 24598: main effect of scopolamine (<italic>P &lt;</italic> 0.0001), ORG 24598 (<italic>P</italic> = 0.0002) and interaction (<italic>P &lt;</italic> 0.0001); and <bold>f</bold> S18841: main effect of scopolamine (<italic>P &lt;</italic> 0.0001), S18841 (<italic>P &lt;</italic> 0.0001) and interaction (<italic>P &lt;</italic> 0.0001). ***<italic>P &lt;</italic> 0.001 between vehicle/scopolamine and vehicle/vehicle; <sup>#</sup><italic>P &lt;</italic> 0.05, <sup>##</sup><italic>P &lt;</italic> 0.01 and <sup>###</sup><italic>P &lt;</italic> 0.001 between drug/scopolamine and vehicle/scopolamine Newman-Keuls post hoc test</p></caption><graphic id="MO2" xlink:href="12035_2020_1875_Fig2_HTML"></graphic></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Comparison of the dose of each glycine modulatory site agonist, partial agonist or GlyT1 inhibitor (GlyT1 I, as indicated in the activity column) to significantly (a) elevate prefrontal cortex (PFC) glycine and D-serine, (b) reverse scopolamine-induced impairment in social recognition (taken from T<sub>2</sub>-T<sub>1</sub> active social investigation time, s) and (c) prevent the 4 h intertrial time delay-induced reduction in NOR (taken from choice trial discrimination ratio, (novel-familiar/total object exploration)). **<italic>P</italic> &lt; 0.01 and ***<italic>P</italic> &gt; 0.001 from vehicle control in that group of rats Dunnett’s post hoc test following ANOVA. NOR = novel object recognition, i.p. = intraperitoneal and s.c. = subcutaneous</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Drug</th><th rowspan="2">Activity</th><th colspan="2">Elevation in PFC microdialysate glycine or D-serine dose mg/kg and route of injection</th><th rowspan="2">Reversal of scopolamine-impaired social recognition dose mg/kg s.c.</th><th rowspan="2">Reversal of time-delay reduction in NOR dose mg/kg i.p.</th></tr><tr><th>Glycine</th><th>D-serine</th></tr></thead><tbody><tr><td>Glycine</td><td>Agonist</td><td>200 i.p.***</td><td>–</td><td>100**</td><td>160*</td></tr><tr><td>D-Serine</td><td>Agonist</td><td>–</td><td>160 s.c. ***</td><td>80**</td><td>40**</td></tr><tr><td>D-Cycloserine</td><td>Partial agonist</td><td>–</td><td>40 s.c. ***</td><td>0.63***</td><td>2.5*</td></tr><tr><td>Sarcosine</td><td>GlyT1 I</td><td>200 i.p.***</td><td>–</td><td>40**</td><td>200*</td></tr><tr><td>ORG24598</td><td>GlyT1 I</td><td>2.5 s.c.***</td><td>–</td><td>0.63***</td><td>2.5**</td></tr><tr><td>S18841</td><td>Partial agonist</td><td>–</td><td>–</td><td>0.31 **</td><td>10**</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="Sec16">
<title>Effect of Glycine Modulatory Drugs on the Delay-Induced Impairment of Novel Object Recognition</title>
<p id="Par21">NOR is a visual learning and memory task considered to have ethological relevance to human declarative memory [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR59">59</xref>] that is both PFC-dependent and impaired in schizophrenia, and its selection is thoroughly considered in the discussion. We therefore performed dose-response studies with all the glycine-modifying compounds to establish their ability to improve a time-delay-induced impairment in NOR. With vehicle injection in all studies, rats were unable to distinguish the novel from the familiar object in the choice trial (Fig. <xref ref-type="fig" rid="Fig3">3</xref> a, c, e, g and i). However, the highest two doses of every agonist or glycine reuptake inhibitor increased the time spent exploring the novel over the familiar object, and even the lowest dose (2.5 mg/kg) of D-cycloserine produced a significant increase. With glycine, D-serine and sarcosine (<italic>F</italic><sub>(3, 44)</sub> = 2.709, <italic>P</italic> = 0.057, <italic>F</italic><sub>(3, 44)</sub> = 7.45, <italic>P &lt;</italic> 0.001, and <italic>F</italic><sub>(3, 44)</sub> = 10.27, <italic>P &lt;</italic> 0.001, respectively), the significant increase in novel object exploration was dose-related, while the improvement seen with D-cycloserine (<italic>F</italic><sub>(3, 44)</sub> = 6.518, <italic>P &lt;</italic> 0.01) was similar at all three doses and with ORG24598 (<italic>F</italic><sub>(3, 44)</sub> = 8.23, <italic>P</italic> &lt; 0.001) only apparent at the highest two doses.<fig id="Fig3"><label>Fig. 3</label><caption><p>Ability of glycine receptor agonists (<bold>a</bold>–<bold>f</bold>) and glycine reuptake inhibitors (<bold>g</bold>–<bold>j</bold>) to reverse natural forgetting in a 4-h intertrial interval novel object recognition paradigm. Comparison of the effect of glycine (<bold>a</bold> and <bold>b</bold>, 40–800 mg/kg, 4 ml/kg), D-serine (<bold>c</bold> and <bold>d</bold>, 10–40 mg/kg, 1 ml/kg), D-cycloserine (<bold>e</bold> and <bold>f</bold>, 2.5–40 mg/kg, 1 ml/kg), sarcosine (<bold>g</bold> and <bold>h</bold>, 40–200 mg/kg, 1 ml/kg) and ORG 24598 (<bold>i</bold> and <bold>j</bold>, 0.63–5 mg/kg, 1 ml/kg) injected s.c. 30 min prior to the familiarisation trial in Lister hooded rats (<italic>n</italic> = 12 unless stated, data shown as mean ± SEM). <bold>a</bold>, <bold>c</bold>, <bold>e</bold>, <bold>g</bold>, <bold>i</bold> Actual novel and familiar object exploration times (s) during the second choice trial; *<italic>P &lt;</italic> 0.05, **<italic>P &lt;</italic> 0.01, ***<italic>P &lt;</italic> 0.001 significantly different from novel object in same treatment group, Bonferroni post hoc following repeated measures ANOVA. <bold>b</bold>, <bold>d</bold>, <bold>f</bold>, <bold>h</bold>, <bold>j</bold> Derived discrimination ratio (novel object exploration–familiar object exploration/total object exploration); *<italic>P &lt;</italic> 0.05, **<italic>P &lt;</italic> 0.01, ***<italic>P &lt;</italic> 0.001 significantly different from vehicle control, Dunnett’s post hoc. In <bold>a</bold>, RM-ANOVA showed that the object × glycine treatment interaction just failed to reach significance (<italic>P</italic> = 0.057). <bold>b</bold> ANOVA showed a significant main effect of glycine treatment (<italic>P &lt;</italic> 0.05). <bold>c</bold> Significant object × D-serine interaction (<italic>P &lt;</italic> 0.001). <bold>d</bold> Significant main effect of D-serine (<italic>P &lt;</italic> 0.001). <bold>e</bold> Significant object × D-cycloserine interaction (<italic>P &lt;</italic> 0.01, <italic>n</italic> = 11). <bold>f</bold> Significant effect of D-cycloserine (<italic>P &lt;</italic> 0.05, <italic>n</italic> = 11). <bold>g</bold> Significant object × sarcosine interaction (<italic>P &lt;</italic> 0.001). <bold>h</bold> Significant main effect of D-serine treatment (<italic>P &lt;</italic> 0.001). <bold>i</bold> Significant object × ORG 24598 treatment interaction (<italic>P &lt;</italic> 0.001). <bold>j</bold> Significant effect of ORG 24598 treatment (<italic>P &lt;</italic> 0.001)</p></caption><graphic id="MO3" xlink:href="12035_2020_1875_Fig3_HTML"></graphic></fig></p>
<p id="Par22">Analysis of the choice trial discrimination ratio data (Fig. <xref ref-type="fig" rid="Fig3">3</xref> b, d, f, h and j) from the same rats confirmed improvement in object discrimination predicted from raw exploration times. In all groups, the discriminated ratio was at or close to chance following vehicle and significantly increased with glycine (<italic>F</italic><sub>(3, 44)</sub> = 3.17, <italic>P &lt;</italic> 0.05; <italic>P &lt;</italic> 0.05 two highest doses), D-serine (<italic>F</italic><sub>(3, 44)</sub> = 9.64, <italic>P &lt;</italic> 0.001; <italic>P &lt;</italic> 0.01 and <italic>P &lt;</italic> 0.001 with 40 and 160 mg/kg, respectively), D-cycloserine (<italic>F</italic><sub>(3, 44)</sub> = 3.73, <italic>P &lt;</italic> 0.05; <italic>P &lt;</italic> 0.05 with all doses), sarcosine (<italic>F</italic><sub>(3, 44)</sub> = 7.88, <italic>P &lt;</italic> 0.001; <italic>P &lt;</italic> 0.001, highest dose only) and ORG24598 (<italic>F</italic><sub>(3, 44)</sub> = 8.72, <italic>P &lt;</italic> 0.001; <italic>P &lt;</italic> 0.01 and <italic>P &lt;</italic> 0.05 at 2.5 and 5 mg/kg, respectively). Thus, as with social recognition, the minimum dose to improve NOR was equivalent to, or lower than, that found to elevate either PFC glycine or D-serine in microdialysates (Table <xref ref-type="table" rid="Tab2">2</xref>), consistent with mechanistic association.</p>
<p id="Par23">No dose of any drug caused a preferential exploration of either object during the familiarisation trial (Table <xref ref-type="table" rid="Tab3">3</xref>), although with sarcosine ANOVA showed a significant (<italic>F</italic><sub>(3, 44)</sub> = 10.27, <italic>P &lt;</italic> 0.001) location × drug interaction. Furthermore, only in the D-serine group was there any main effect of drug on total object exploration time in the familiarisation trial (<italic>F</italic><sub>(3, 44)</sub> = 2.98, <italic>P &lt;</italic> 0.05) and this was not dose-related. In all other groups, there was no effect of drug treatment on total exploration in either familiarisation or choice trials (Table <xref ref-type="table" rid="Tab3">3</xref>). Therefore, alteration of choice trial object exploration by all five drugs resulted from redistribution of attention towards the novel object, consistent with a specific effect on visual learning and memory and not a reduction in attention to both objects.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Object exploration during familiarisation and choice trials with glycine agonists and GlyT1 inhibitors, accompanying Fig. <xref ref-type="fig" rid="Fig3">3</xref>. Time (s, mean (SEM)) spent exploring (from left to right) front and back object and both objects during the (first) familiarisation trial and total time exploring both objects in the (second) choice trial in the novel object recognition test. For each glycine site agonist or glycine transporter-1 inhibitor, three doses (as stated) were compared to the effect of vehicle (s.c.) given in a balanced quasi-random order over 4 weeks in five separate groups of group-housed male Lister Hooded rats. Following D-serine administration there was a significant main effect of drug treatment on total object exploration during the familiarisation trial (<italic>P</italic> &lt; 0.05). There was no preference for the location of the object during the familiarisation trial in any drug group, but following treatment with sarcosine there was a significant location x drug interaction (<italic>P</italic> &lt; 0.05). There was no significant effect of any drug on total exploration during the choice trial (all <italic>P</italic> &gt; 0.05). *<italic>P</italic> &lt; 0.05 from vehicle at that time point, Dunnett’s post hoc following ANOVA</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th></th><th colspan="2">Familiarisation trial</th><th colspan="2">Choice trial</th></tr><tr><th>Drug</th><th>Dose</th><th>Front object (s)</th><th>Back object (s)</th><th>Total exploration (s)</th><th>Total exploration (s)</th></tr></thead><tbody><tr><td>Glycine (<italic>n</italic> = 12)</td><td><p>Vehicle</p><p>40 mg/kg</p><p>160 mg/kg</p><p>800 mg/kg</p></td><td><p>5.5 (0.4)</p><p>6.9 (0.9)</p><p>7.0 (0.8)</p><p>6.9 (0.9)</p></td><td><p>5.7 (0.6)</p><p>8.0 (1.0)</p><p>6.2 (0.6)</p><p>6.3 (0.9)</p></td><td><p>11.2 (0.8)</p><p>14.9 (1.8)</p><p>13.2 (1.2)</p><p>13.2 (1.6)</p></td><td><p>10.8 (1.1)</p><p>10.9 (1.5)</p><p>12.1 (1.6)</p><p>13.7 (2.1)</p></td></tr><tr><td>D-Serine (<italic>n</italic> = 12)</td><td><p>Vehicle</p><p>10 mg/kg</p><p>40 mg/kg</p><p>160 mg/kg</p></td><td><p>5.8 (1.0)</p><p>6.7 (0.7)</p><p>9.0 (0.9)</p><p>5.7 (0.9)</p></td><td><p>5.5 (0.8)</p><p>7.9 (0.8)</p><p>8.6 (1.3)</p><p>6.7 (0.6)</p></td><td><p>11.3 (1.7)</p><p>14.6 (1.2)</p><p>17.7 (2.2)*</p><p>12.3 (1.3)</p></td><td><p>12.1 (2.3)</p><p>9.8 (1.3)</p><p>9.9 (1.7)</p><p>11.7 (1.9)</p></td></tr><tr><td>D-Cycloserine (<italic>n</italic> = 11)</td><td><p>Vehicle</p><p>2.5 mg/kg</p><p>10 mg/kg</p><p>40 mg/kg</p></td><td><p>7.5 (0.9)</p><p>6.3 (0.6)</p><p>5.5 (0.7)</p><p>6.5 (0.8)</p></td><td><p>7.6 (0.8)</p><p>6.5 (0.6)</p><p>6.7 (0.7)</p><p>6.9 (1.4)</p></td><td><p>15.1 (1.5)</p><p>12.7 (1.0)</p><p>12.2 (1.2)</p><p>13.5 (2.2)</p></td><td><p>7.5 (1.1)</p><p>9.7 (1.1)</p><p>8.6 (1.3)</p><p>11.8 (1.2)</p></td></tr><tr><td>Sarcosine (<italic>n</italic> = 12)</td><td><p>Vehicle</p><p>40 mg/kg</p><p>80 mg/kg</p><p>200 mg/kg</p></td><td><p>6.0 (0.7)</p><p>4.5 (0.4)</p><p>5.1 (0.6)</p><p>5.5 (0.4)</p></td><td><p>4.1 (0.4)</p><p>4.8 (0.6)</p><p>5.3 (0.4)</p><p>5.6 (0.5)</p></td><td><p>10.1 (1.0)</p><p>9.3 (0.8)</p><p>10.3 (0.8)</p><p>11.1 (0.7)</p></td><td><p>9.2 (1.3)</p><p>7.8 (1.2)</p><p>8.7 (1.1)</p><p>7.9 (1.3)</p></td></tr><tr><td>ORG 24598 (<italic>n</italic> = 12)</td><td><p>Vehicle</p><p>0.63 mg/kg</p><p>2.5 mg/kg</p><p>5 mg/kg</p></td><td><p>5.0 (0.8)</p><p>5.9 (1.0)</p><p>8.4 (1.2)</p><p>6.9 (0.9)</p></td><td><p>6.1 (0.8)</p><p>7.2 (1.0)</p><p>7.4 (1.1)</p><p>6.9 (0.7)</p></td><td><p>11.1 (1.5)</p><p>13.1 (1.6)</p><p>15.8 (2.1)</p><p>13.8 (1.3)</p></td><td><p>10.3 (2.0)</p><p>9.5 (1.7)</p><p>12.2 (1.4)</p><p>13.8 (1.5)</p></td></tr></tbody></table></table-wrap></p>
<p id="Par24">Acute pretreatment with the glycine site partial agonist, S18841 (0.63 to 10 mg/kg s.c.), reversed a time delay-induced impairment in NOR (Fig. <xref ref-type="fig" rid="Fig4">4</xref> a and b). With a 4 h ITI, vehicle-treated rats were unable to distinguish the novel from the familiar object in the choice trial (Fig. <xref ref-type="fig" rid="Fig4">4a</xref>) as expected [<xref ref-type="bibr" rid="CR54">54</xref>]. S18841 produced a dose-related restoration of preferential novel object exploration (Fig. <xref ref-type="fig" rid="Fig4">4a</xref> object × S18841; <italic>F</italic><sub>(3, 40)</sub> = 3.02, <italic>P &lt;</italic> 0.05), confirmed by the discrimination ratio (Fig. <xref ref-type="fig" rid="Fig4">4b</xref>, <italic>F</italic><sub>(3, 40)</sub> = 3.70, <italic>P &lt;</italic> 0.05) being significantly (<italic>P &lt;</italic> 0.01) greater than vehicle with the highest dose (10 mg/kg). There was no preference for either object and no main effect of drug treatment during the familiarisation trial (Table <xref ref-type="table" rid="Tab4">4</xref>). Similarly S18841 had no effect on total object exploration during either the familiarisation (Table 4) or choice trials confirming a specific pro-cognitive effect of S18841.<fig id="Fig4"><label>Fig. 4</label><caption><p>Restoration of a time-delay impairment (natural forgetting) in novel object recognition by the partial glycine agonist, S18841, is prevented by the glycine antagonist, L701,324, and the NMDA receptor antagonist, CPP. S18841 (in <bold>a</bold> and <bold>b</bold> 0.63–10 mg/kg, in <bold>c</bold> and <bold>d</bold> 10 mg/kg) or vehicle (1 ml/kg) injected s.c. 30 min prior to the familiarisation trial in Lister hooded rats. CPP (20 mg/kg, 1 ml/kg), L701,324 (10 mg/kg, 4 ml/kg) or vehicle (1 ml/kg) injected i.p. 20 min prior to the familiarisation trial in <bold>c</bold> and <bold>d</bold>. The partial glycine agonist, S18841, delayed natural forgetting in the novel object discrimination paradigm when discretely injected into the prefrontal cortex (<bold>e</bold> and <bold>f</bold>) but not the striatum (<bold>g</bold> and <bold>h</bold>). S18841 (2.5 μg or 10 μg/side) or vehicle (1 μl/side) injected 5 min prior to the familiarisation trial in group-housed male Lister hooded rats. Data presented as mean ± SEM. <bold>a</bold>, <bold>c</bold>, <bold>e</bold>, <bold>g</bold> Actual novel and familiar object exploration time (s) during the second choice trial. <bold>b</bold>, <bold>d</bold>, <bold>f</bold>, <bold>h</bold> Derived discrimination ratio (novel object exploration–familiar object exploration/total object exploration). In <bold>a</bold>, RM-ANOVA showed a significant object × S18841 treatment interaction (<italic>P &lt;</italic> 0.05), *<italic>P &lt;</italic> 0.05 from novel object in same treatment group, Bonferroni post hoc. <bold>b</bold> ANOVA showed a significant effect of S18841 treatment (<italic>P &lt;</italic> 0.05), **<italic>P &lt;</italic> 0.01 from vehicle, Dunnett’s post hoc. <bold>c</bold> RM-ANOVA significant object × S18841 treatment (<italic>P &lt;</italic> 0.01) and object × CPP/L701,324 interactions (<italic>P &lt;</italic> 0.001), ***<italic>P &lt;</italic> 0.001 from novel object in same treatment group, Bonferroni post hoc<italic>.</italic><bold>d</bold> ANOVA showed a significant effect of S18841 treatment (<italic>P &lt;</italic> 0.05) and a significant effect of CPP/L701,324 (<italic>P &lt;</italic> 0.01), **<italic>P &lt;</italic> 0.01 from vehicle<bold>/</bold>vehicle; <sup>++</sup><italic>P &lt;</italic> 0.01, <sup>+++</sup><italic>P &lt;</italic> 0.001 from S18841/vehicle, Fishers LSD post hoc. <bold>e</bold> RM-ANOVA showed a significant object × S18841 treatment interaction (<italic>P &lt;</italic> 0.05), **<italic>P &lt;</italic> 0.01, ***<italic>P &lt;</italic> 0.001 from novel object in same treatment group, Bonferroni post hoc. <bold>f</bold> ANOVA showed a significant effect of S18841 treatment (<italic>P &lt;</italic> 0.05), *<italic>P &lt;</italic> 0.05 from vehicle, Dunnett’s post hoc. <bold>g</bold> RM-ANOVA no significant object × S18841 treatment interaction (<italic>P</italic> = 0.510). <bold>h</bold>, ANOVA showed a no significant effect of S18841 treatment (<italic>P</italic> = 0.531)</p></caption><graphic id="MO4" xlink:href="12035_2020_1875_Fig4_HTML"></graphic></fig><table-wrap id="Tab4"><label>Table 4</label><caption><p>Object exploration during familiarisation and choice novel object recognition trials accompanying Figs. <xref ref-type="fig" rid="Fig3">3</xref> and <xref ref-type="fig" rid="Fig4">4</xref>. As detailed in Table <xref ref-type="table" rid="Tab2">2</xref> legend, object exploration times (s) in the familiarisation and choice trials during the novel object recognition task shown as mean (SEM). In descending order, the groups show (1) the dose-response to systemic administration of the glycine site partial agonist, S18841 alone, (2) S18841 combined with administration of either the NMDA receptor antagonist CPP or the glycine site antagonist L701,324, or S18841 given by discrete microinjection into either the (3) medial prefrontal cortex (PFC) or (4) the striatum. None of the drugs had any effect on either the total object exploration or distribution of object exploration during the familiarisation trial in any of the studies (all <italic>P</italic> &gt; 0.05). Treatment with CPP/ L701,324 significantly reduced total familiarisation trial exploration (<italic>P</italic> &lt; 0.05), and in that study, there was also an effect of S18841 treatment (<italic>P</italic> &lt; 0.05). *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001 significantly different from vehicle/vehicle group at that time point; <sup>+</sup><italic>P</italic> &lt; 0.05 significantly different from S18841/vehicle group at that time point, Fisher LSD post hoc. PFC, prefrontal cortex</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="2">Dose of S18841</th><th colspan="3">Familiarisation trial</th><th>Choice trial</th></tr><tr><th>Front object (s)</th><th>Back object (s)</th><th>Total exploration (s)</th><th>Total exploration (s)</th></tr></thead><tbody><tr><td><p>Vehicle</p><p>0.63 mg/kg</p><p>2.5 mg/kg</p><p>10 mg/kg</p></td><td><p>(<italic>n</italic> = 11)</p><p>(<italic>n</italic> = 11)</p><p>(<italic>n</italic> = 11)</p><p>(<italic>n</italic> = 11)</p></td><td><p>8.9 (1.4)</p><p>7.8 (1.6)</p><p>6.6 (1.4)</p><p>5.8 (0.9)</p></td><td><p>8.5 (1.1)</p><p>7.8 (1.3)</p><p>7.0 (1.7)</p><p>6.2 (0.8)</p></td><td><p>17.4 (2.4)</p><p>15.6 (2.6)</p><p>13.6 (2.9)</p><p>12.0 (1.6)</p></td><td><p>13.3 (2.7)</p><p>13.8 (1.3)</p><p>12.5 (2.1)</p><p>12.2 (1.3)</p></td></tr><tr><td><p>Vehicle/Vehicle</p><p>S18841<sup>a</sup>/Vehicle</p><p>S18841<sup>a</sup>/CPP<sup>b</sup></p><p>S18841<sup>a</sup>/L701324<sup>a</sup></p></td><td><p>(<italic>n</italic> = 12)</p><p>(<italic>n</italic> = 12)</p><p>(<italic>n</italic> = 12)</p><p>(<italic>n</italic> = 12)</p></td><td><p>9.4 (0.8)</p><p>7.8 (0.9)</p><p>5.8 (0.9)</p><p>4.5 (0.9)</p></td><td><p>9.5 (1.0)</p><p>6.8 (0.7)</p><p>4.8 (0.6)</p><p>5.4 (0.7)</p></td><td><p>18.9 (1.6)</p><p>14.7 (1.5)*</p><p>10.7 (1.2)**</p><p>9.9 (1.3)*** <sup>+</sup></p></td><td><p>13.6 (1.6)</p><p>10.5 (1.4)</p><p>8.3 (1.4)</p><p>6.6 (1.3)</p></td></tr><tr><td><p>Vehicle, PFC</p><p>2.5 μg/side</p><p>10 μg/side</p></td><td><p>(<italic>n</italic> = 16)</p><p>(<italic>n</italic> = 8)</p><p>(<italic>n</italic> = 8)</p></td><td><p>13.5 (1.6)</p><p>13.3 (1.2)</p><p>12.5 (1.7)</p></td><td><p>13.1 (1.9)</p><p>13.9 (2.2)</p><p>12.9 (1.7)</p></td><td><p>26.5 (3.0)</p><p>27.2 (3.0)</p><p>25.3 (3.2)</p></td><td><p>23.2 (1.2)</p><p>19.5 (3.0)</p><p>21.4 (2.8)</p></td></tr><tr><td><p>Vehicle, striatum</p><p>10 μg/side</p></td><td><p>(<italic>n</italic> = 8)</p><p>(<italic>n</italic> = 8)</p></td><td><p>18.2 (3.2)</p><p>17.8 (1.4)</p></td><td><p>20.4 (3.7)</p><p>17.8 (1.8)</p></td><td><p>38.5 (6.6)</p><p>35.6 (2.9)</p></td><td><p>21.6 (2.1)</p><p>21.6 (1.3)</p></td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="Sec17">
<title>Prevention of the Pro-cognitive Effect of S18841 on NOR by Blockade of NMDA Receptors</title>
<p id="Par25">To establish the downstream role of NMDA receptor activation in the effect of S18841 on recognition memory, we showed that the glycine modulatory site antagonist, L701,324, and the NMDA receptor antagonist, CPP, completely prevented the reversal of impairment of NOR by S18841 (Fig. <xref ref-type="fig" rid="Fig4">4</xref> c and d). Akin to data in the dose-response study, vehicle-treated rats were unable to discriminate novel and familiar objects but S18841 (10 mg/kg) restored novel object preference (Fig. <xref ref-type="fig" rid="Fig4">4c</xref> object × S18841; <italic>F</italic><sub>(1, 40)</sub> = 12.29, <italic>P &lt;</italic> 0.01). Of note, co-treatment with either CPP or L701,324 prevented the S18841-induced reversal (object × CPP/L701,324; <italic>F</italic><sub>(2, 44)</sub> = 14.660, <italic>P &lt;</italic> 0.001. Furthermore, the significant increase in discrimination ratio in the S18841/vehicle group (Fig. <xref ref-type="fig" rid="Fig4">4d</xref>, <italic>F</italic><sub>(1, 44)</sub> = 6.79, <italic>P &lt;</italic> 0.05) was abolished by S18841/CPP and S18841/L701,324 combinations (<italic>F</italic><sub>(2, 40)</sub> = 8.82, <italic>P &lt;</italic> 0.01), the ratio being significantly less (<italic>P &lt;</italic> 0.001 and <italic>P &lt;</italic> 0.01, respectively) with CPP and L701,324 than with vehicle/S18841 treatment. Both CPP and L701,324 reduced total object exploration in the familiarisation trial (Table <xref ref-type="table" rid="Tab3">3</xref>; S18841; <italic>F</italic><sub>(1, 44)</sub> = 4.56, <italic>P</italic> &lt; 0.05, CPP/L701,324; <italic>F</italic><sub>(1, 44)</sub> = 3.29, <italic>P</italic> &lt; 0.05), but there were no significant changes in total choice trial exploration. Despite total exploration being reduced, there was no object preference (Table <xref ref-type="table" rid="Tab4">4</xref>) and neither treatment effected the distribution of object exploration during the familiarisation trial.</p>
</sec>
<sec id="Sec18">
<title>Reversal of Delay-Dependent Impairment of NOR by Intra-PFC S18841</title>
<p id="Par26">Consistent with the involvement of the PFC in the pro-cognitive effects of S18841, bilateral PFC microinjection of S18841 reversed the delay-dependent impairment of NOR (Fig. <xref ref-type="fig" rid="Fig4">4e</xref>, object × S18841; <italic>F</italic><sub>(2, 29)</sub> = 4.11, <italic>P &lt;</italic> 0.05) such that rats given either dose spent significantly more (<italic>P &lt;</italic> 0.01 and <italic>P &lt;</italic> 0.001) time exploring the novel object. PFC injection of S18841 also increased the derived discrimination ratio (Fig. <xref ref-type="fig" rid="Fig4">4f</xref>, <italic>F</italic><sub>(2, 29)</sub> = 4.68, <italic>P &lt;</italic> 0.05) such that it was significantly greater than vehicle (<italic>P &lt;</italic> 0.05). In contrast, injecting S18841 into the striatum at the higher dose failed to enhance exploration of the novel object (Fig. <xref ref-type="fig" rid="Fig4">4g</xref>) or alter the discrimination ratio (Fig. <xref ref-type="fig" rid="Fig4">4h</xref>). Bilateral microinjections of S18841 into the PFC or striatum had no effect on total object exploration during either the familiarisation or choice trials (Table <xref ref-type="table" rid="Tab4">4</xref>), emphasising that improvement in visual recognition memory was not due to changes in locomotor activity or inattention to the objects during acquisition. In addition, irrespective of the site of S18841 microinjection, it did not alter the distribution of object exploration during the familiarisation trial (Table <xref ref-type="table" rid="Tab4">4</xref>). Histological analysis confirmed the site of the microinjections in all rats (see <xref ref-type="media" rid="MOESM1">online resource</xref>; Fig. <xref ref-type="media" rid="MOESM1">S1</xref>).</p>
</sec>
<sec id="Sec19">
<title>Effect of S18841 upon Hyperactivity of Isolation-Reared Rats</title>
<p id="Par27">Commencing 5 weeks after weaning, rats underwent a battery of behavioural tasks (Fig. <xref ref-type="fig" rid="Fig5">5a</xref>), the first being placed in an unfamiliar chamber without drug administration to confirm that isolation induced the expected novelty-induced hyperactivity (supplementary Fig. <xref ref-type="media" rid="MOESM1">S2A</xref>, <italic>F</italic><sub>(1, 48)</sub> = 16.70, <italic>P &lt;</italic> 0.001). Isolation-reared rats showed greater horizontal activity over time (time × housing; <italic>F</italic><sub>(11, 528)</sub> = 3.29, <italic>P &lt;</italic> 0.001) when introduced to the chamber compared to their group-housed littermates, confirming development of the ‘isolation syndrome’. In addition to hyperactivity, as expected, isolated rats displayed significantly more rears over 1 h than group-housed controls (<xref ref-type="media" rid="MOESM1">online resource</xref>; Fig. <xref ref-type="media" rid="MOESM1">S2B</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p><bold>a</bold> Time course protocol for sequential assessment of locomotor activity (LMA), novel object recognition (NOR) and conditioned freezing in rats placed in individual cages (social isolation) or group-housed (littermate controls) from weaning on post natal day 24. Effect of the partial glycine agonist, S18841, on <bold>b</bold> locomotor activity and <bold>c</bold> number of rears observed over 1 h in a novel arena, <bold>d</bold> novel and familiar object exploration time (s) and <bold>e</bold> the derived discrimination ratio (novel object exploration–familiar object exploration/total object exploration) during the second choice trial of novel object recognition. Also in the conditioned freezing task, the total freezing time (s) <bold>f</bold> after the first two of three foot shocks during conditioning and <bold>g</bold> upon reintroduction into the chamber 24 h after conditioning and again 48 h after conditioning both before (Pre-Cue) and after presentation of the cue alone (Post-Cue), as indicated. Rats were either group-housed (Social) or single housed (Isolate) from weaning on post-natal day 24. S18841 (2.5 or 10 mg/kg s.c.) or vehicle (1 ml/kg) was injected 30 min prior to <bold>b</bold>, <bold>c</bold> being placed in the arena for 1 h, <bold>d</bold>, <bold>e</bold> before the familiarisation trial and <bold>f</bold>, <bold>g</bold> before receiving foot shock conditioning in the associative learning paradigm. Data expressed as mean ± SEM, <italic>n</italic> = 10 per group. In <bold>b</bold>, RM-ANOVA showed a significant main effect of housing (<italic>P &lt;</italic> 0.001) but not drug treatment (<italic>P</italic> = 0.283). *<italic>P &lt;</italic> 0.05 from social/vehicle rats; <sup>++</sup><italic>P &lt;</italic> 0.01 from social/10 mg/kg S18841, Fishers LSD. <bold>c</bold> RM-ANOVA revealed a significant main effect of housing (<italic>P &lt;</italic> 0.001) but not drug treatment (<italic>P</italic> = 0.317). *<italic>P &lt;</italic> 0.05 from social/vehicle rats; <sup>+</sup><italic>P &lt;</italic> 0.05, <sup>++</sup><italic>P &lt;</italic> 0.01 from social/10 mg/kg S18841, Fishers LSD. <bold>d</bold> RM-ANOVA showed a significant object × S18841 treatment (<italic>P &lt;</italic> 0.05) and object × S18841 treatment × housing (<italic>P &lt;</italic> 0.001) interaction, ***<italic>P &lt;</italic> 0.001 from novel object in same treatment group, Bonferroni post hoc. <bold>e</bold> ANOVA revealed a significant main effect of housing (<italic>P &lt;</italic> 0.05) and S18841 treatment (<italic>P &lt;</italic> 0.001) and a significant housing × S18841 interaction (<italic>P &lt;</italic> 0.001), *<italic>P &lt;</italic> 0.05, ***<italic>P &lt;</italic> 0.001 from social/vehicle. <bold>f</bold> RM-ANOVA indicated a significant conditioning × housing interaction (<italic>P &lt;</italic> 0.05) and a main effect of housing (<italic>P &lt;</italic> 0.001), *<italic>P &lt;</italic> 0.05, ***<italic>P &lt;</italic> 0.001 significantly different from social/vehicle at that time point; <sup>+</sup><italic>P &lt;</italic> 0.05, <sup>++</sup><italic>P &lt;</italic> 0.01, <sup>+++</sup><italic>P &lt;</italic> 0.001 from social/10 mg/kg S18841, Fisher LSD post hoc. <bold>g</bold> At 24 h post-conditioning ANOVA indicated a significant main effect of housing (<italic>P &lt;</italic> 0.001) and S18841 treatment (<italic>P &lt;</italic> 0.05). At 48 h, there was no main effect of housing or S18841 treatment pre-cue but there was a main effect of housing post cue (<italic>P &lt;</italic> 0.001), *<italic>P &lt;</italic> 0.05, **<italic>P &lt;</italic> 0.01 from social/vehicle; <sup>+</sup><italic>P &lt;</italic> 0.05, <sup>++</sup><italic>P &lt;</italic> 0.01, <sup>+++</sup><italic>P &lt;</italic> 0.001 from social/10 mg/kg S18841, <sup>##</sup><italic>P &lt;</italic> 0.01 from isolate/vehicle Fisher LSD post hoc</p></caption><graphic id="MO5" xlink:href="12035_2020_1875_Fig5_HTML"></graphic></fig></p>
<p id="Par28">Six weeks after weaning, rats were pretreated with S18841 (2.5 or 10 mg/kg) or vehicle before being re-introduced into the chamber (Fig. <xref ref-type="fig" rid="Fig5">5a</xref>). As expected, the socially isolated rats were hyperactive (Fig. <xref ref-type="fig" rid="Fig5">5b</xref>, <italic>F</italic><sub>(1, 45)</sub> = 14.22, <italic>P &lt;</italic> 0.001) but S18841 had no significant effect on locomotor activity in group-housed or isolated rats. Similarly, the increase in total rears in the isolated rats (Fig. <xref ref-type="fig" rid="Fig5">5c</xref>, <italic>F</italic><sub>(1, 45)</sub> = 16.42, <italic>P &lt;</italic> 0.001) was unaltered by S18841. This suggests that the partial glycine agonist may have little effect on the augmentation of ventral tegmental dopaminergic activation of the nucleus accumbens thought to contribute to the isolation-induced hyperactive response to a novel environment.</p>
</sec>
<sec id="Sec20">
<title>Reversal of NOR Deficits in Isolation-Reared Rats by S18841</title>
<p id="Par29">The effect of S18841 on NOR in isolation-reared rats was examined to ascertain if it could reverse a neurodevelopmental impairment in visual recognition memory (Fig. <xref ref-type="fig" rid="Fig5">5</xref> d and e). S18841 reversed the impairment of NOR seen in isolation-reared rats, ANOVA showing an object × S18841 treatment (<italic>F</italic><sub>(2, 45)</sub> = 3.84, <italic>P &lt;</italic> 0.05) and object × housing × S18841 treatment (<italic>F</italic><sub>(1, 45)</sub> = 22.89, <italic>P &lt;</italic> 0.001) interaction (Fig. <xref ref-type="fig" rid="Fig5">5d</xref>). Analysis of the derived discrimination ratio (Fig. <xref ref-type="fig" rid="Fig5">5e</xref>) showed a significant main effect of housing (<italic>F</italic><sub>(1, 45)</sub> = 7.06, <italic>P &lt;</italic> 0.05), confirming that this index of NOR was also significantly greater in isolated rats treated with either dose of S18841 (2.5 mg/kg; <italic>P &lt;</italic> 0.01, 10 mg/kg; <italic>P &lt;</italic> 0.001) than in vehicle-treated isolates, consistent with the drug-induced reversal of the neurodevelopmental cognitive impairment. Rats did not show any preferential exploration of the identical objects in the familiarisation trial (Table <xref ref-type="table" rid="Tab5">5</xref>), irrespective of housing condition during development or drug treatment. Furthermore, during both familiarisation and choice NOR trials, total object exploration was greater in the isolated groups but unaffected by drug treatment (Table <xref ref-type="table" rid="Tab5">5</xref>). Thus, the improvement in NOR produced by S18841 in isolation-reared rats was not due to increased object attention during acquisition but a preferential improvement in visual recognition memory.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Object exploration during the familiarisation and choice trials in the novel object recognition task in rat littermates reared from weaning either as a group or in social isolation accompanying Fig. <xref ref-type="fig" rid="Fig5">5</xref> in the manuscript. As detailed in Table <xref ref-type="table" rid="Tab2">2</xref> legend, object exploration times (s) in the familiarisation and choice trials (separated by a 2 h interval) during the novel object discrimination task shown as mean (SEM), <italic>n</italic> = 10 per group. Rats were injected with either S18841 (2.5 or 10 mg/kg) or vehicle (1 ml/kg) s.c. 30 min prior to start of task. During the familiarisation trial, although there was no significant difference between the exploration of the front and back object, there was a significant location × housing (<italic>P</italic> &lt; 0.01) and location × S18841 treatment (<italic>P</italic> &lt; 0.05) interaction. During both the familiarisation and choice trials, ANOVA showed a main effect of housing (<italic>P</italic> &lt; 0.05 and <italic>P</italic> &lt; 0.01, respectively). However, post hoc analysis revealed that the only significant differences were between the group-housed (social) rats administered S18841 and the isolation-reared rats, <sup>+</sup><italic>P</italic> &lt; 0.05, <sup>++</sup><italic>P</italic> &lt; 0.01 significantly different from social/10 mg/kg S18841 group during that trial, Fisher LSD post hoc</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Housing</th><th rowspan="2">Drug</th><th colspan="3">Familiarisation trial</th><th>Choice trial</th></tr><tr><th>Front object (s)</th><th>Back object (s)</th><th>Total exploration (s)</th><th>Total exploration (s)</th></tr></thead><tbody><tr><td><p>Social</p><p>Social</p><p>Isolate</p><p>Isolate</p><p>Isolate</p></td><td><p>Vehicle</p><p>10 mg/kg</p><p>Vehicle</p><p>2.5 mg/kg</p><p>10 mg/kg</p></td><td><p>15.9 (1.5)</p><p>12.3 (2.0)</p><p>13.7 (1.1)</p><p>15.4 (1.6)</p><p>14.1 (1.9)</p></td><td><p>14.8 (2.1)</p><p>11.3 (2.1)</p><p>19.5 (1.4)</p><p>14.8 (1.5)</p><p>18.8 (1.8)</p></td><td><p>31.2 (3.5)</p><p>25.8 (3.0)</p><p>33.2 (1.4)<sup>+</sup></p><p>30.2 (2.6)</p><p>32.9 (3.5)<sup>+</sup></p></td><td><p>28.7 (1.7)</p><p>22.4 (2.3)</p><p>32.9 (2.2)<sup>++</sup></p><p>29.8 (1.7)<sup>++</sup></p><p>28.7 (2.4)<sup>+</sup></p></td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="Sec21">
<title>Partial Reversal of CFR Deficits in Isolation-Reared Rats by S18841</title>
<p id="Par30">As reported previously, social isolation from weaning induces deficits in contextual and conditioned associative learning in the CFR task (Fig. <xref ref-type="fig" rid="Fig5">5</xref> f and g) which is thought to have translational relevance to negative valence systems in man. Neither isolation housing nor S18841 treatment altered the latency of rats to cross from the more aversive light to the dark side (data not shown) during conditioning, indicating that alterations in CFR were not confounded by changes in anxiety or locomotor activity. However, freezing after each shock during conditioning was significantly lower in isolates than group-housed rats (Fig. <xref ref-type="fig" rid="Fig5">5f</xref>, housing; <italic>F</italic><sub>(1, 45)</sub> = 1.57, <italic>P &lt;</italic> 0.001) but increased with each conditioning shock, as in group-housed controls, and S18841 had no effect. Vehicle-treated isolated rats froze for significantly less time than vehicle-treated group-housed littermates (<italic>P &lt;</italic> 0.01) when placed back in the conditioning context 24 h later (Fig. <xref ref-type="fig" rid="Fig5">5g</xref>). ANOVA showed a main effect of housing (<italic>F</italic><sub>(1, 45)</sub> = 20.09, <italic>P &lt;</italic> 0.001) and S18841 (<italic>F</italic><sub>(2, 45)</sub> = 7.77, <italic>P &lt;</italic> 0.01), such that isolates administered the highest dose of S18841 froze significantly more (<italic>P &lt;</italic> 0.01) than vehicle isolates and S18841 restored freezing time in isolates to a level comparable to vehicle group-housed rats. In contrast, freezing time was equivalent in all groups when rats were reintroduced to the context at 48 h post-conditioning, suggesting that extinction was unaltered by housing condition or S18841. However, presentation of the CS 48 h after conditioning increased freezing duration in group-housed more than in isolated rats (Fig. <xref ref-type="fig" rid="Fig5">5g</xref>, <italic>F</italic><sub>(1, 45)</sub> = 17.45, <italic>P &lt;</italic> 0.001), but this was not reversed by S18841.</p>
</sec>
</sec>
<sec id="Sec22">
<title>Discussion</title>
<p id="Par31">Overall, the current study is the first comprehensive comparison of the glycine reuptake inhibitors, sarcosine and ORG24598, the agonists, glycine and D-serine and the partial agonists, S18841 and D-cycloserine on PFC microdialysate amino acid and amine levels and cognitive paradigms in normal rats and a neurodevelopmental model for schizophrenia. Both glycine and GlyT1 inhibitors specifically elevated PFC glycine, while D-serine, and to a lesser extent D-cycloserine, elevated D-serine levels, whereas S18841 had no effect on either amino acid (Table <xref ref-type="table" rid="Tab2">2</xref>). All drugs dose-dependently prevented scopolamine-induced impairment of social recognition in adult rats and over similar dose-ranges attenuated a time-delay-induced reduction of NOR (Table <xref ref-type="table" rid="Tab2">2</xref>). Reversal of NOR deficits by systemic S18841 was prevented by the NMDA receptor antagonist, CPP, and the glycine modulatory site antagonist, L701,324, and the effect of S18841 on NOR replicated by microinjection into the PFC. S18841 also reversed the deficit in NOR and impairment in contextual freezing in a conditioned associative learning task in rats reared in social isolation from weaning (a neurodevelopmental model for schizophrenia). The potential relevance of these findings to cognitive impairments seen in schizophrenia is discussed in detail below.</p>
<sec id="Sec23">
<title>Modulation of Extracellular Amino Acids Levels of in PFC</title>
<p id="Par32">Consistent with extracellular glycine being tightly regulated by GlyT1, and previous work with GlyT1 inhibitors in striatal microdialysates, sarcosine and ORG24598 elevated PFC glycine [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR67">67</xref>–<xref ref-type="bibr" rid="CR70">70</xref>] although striatal elevations may be more marked than those in the PFC [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Notably, doses of bitopertin achieving high GlyT1 occupancy in humans also elevated CSF glycine suggesting translational pertinence of rat microdialysis studies [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. Both ORG24598 and sarcosine specifically elevated glycine, without effecting D-serine, other amino acids or acetylcholine, which could contribute to their cognitive effects (Table <xref ref-type="table" rid="Tab1">1</xref>). The only other change was a modest increase in dopamine by sarcosine (Table <xref ref-type="table" rid="Tab1">1</xref>).</p>
<p id="Par33">These observations are important since, to our knowledge, this is the first comprehensive neurochemical characterisation of sarcosine, despite its extensive use as a specific “GlyT1 inhibitor” and an adjunctive agent in schizophrenia patients [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. Lack of change in 5-HT is important given concerns about a potential interaction with serotonergic transmission at a clinical dose of 2 g [<xref ref-type="bibr" rid="CR75">75</xref>] and a transient elevation of rat PFC 5-HT with an extremely high dose (2 g/kg p.o.) of sarcosine [<xref ref-type="bibr" rid="CR76">76</xref>].</p>
<p id="Par34">Glycine also elevated dialysate dopamine (and norepinephrine but not 5-HT), the rise being more pronounced than with GlyT1 inhibitors, and completely selective (Table <xref ref-type="table" rid="Tab1">1</xref>) versus other amino acids [<xref ref-type="bibr" rid="CR51">51</xref>]. It is unclear how glycine elevates dopamine and norepinephrine levels, but this effect is unlikely to involve NMDA receptor recruitment as other glycine site agonists had no effect. One possibility might be a modification of GABA interneuron input to dopaminergic pathways [<xref ref-type="bibr" rid="CR77">77</xref>]. Increased PFC dopamine release may be advantageous to elevate cognitive and negative symptoms in man [<xref ref-type="bibr" rid="CR37">37</xref>].</p>
<p id="Par35">In a mirror image of glycine, D-serine markedly elevated D-serine without affecting glycine [<xref ref-type="bibr" rid="CR51">51</xref>] or other amines including 5-HT, suggesting that the slight increase in 5-HT in a previous dialysis study [<xref ref-type="bibr" rid="CR76">76</xref>] resulted from an unselective effect of the much higher dose (2 g/kg) used. Extracellular cortical D-serine levels are dynamically regulated by alanine-serine-cysteine transporters and reflect both neuronal and glial origin [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>].</p>
<p id="Par36">A previous microdialysis study reported that systemic D-cycloserine elevated PFC D-serine levels [<xref ref-type="bibr" rid="CR80">80</xref>], both in wild-type and serine racemase knockout mice, so it is unlikely to reflect altered synthesis [<xref ref-type="bibr" rid="CR81">81</xref>]. We confirm herein that D-cycloserine modestly increased PFC dialysis D-serine, again without affecting other amino acids or neurotransmitters (Table <xref ref-type="table" rid="Tab1">1</xref>). As proposed by Horio et al. [<xref ref-type="bibr" rid="CR81">81</xref>], metabolism of D-cycloserine to D-serine may account for this rise rather than any effect on the glycine site, since neither S18841 (which cannot be transformed into D-serine) nor the antagonist, L701,324, affected D-serine. Moreover, D-serine was unaltered by the other partial agonists. Finally, S18841 exerted no influence at all on extracellular levels of any amino acid (including aspartate and taurine, not shown) or neurotransmitter encouraging us to focus on this pharmacological tool for further studies.</p>
<p id="Par37">Importantly, demonstration of the highly selective action of sarcosine, ORG24598, glycine (on glycine) and D-serine and D-cycloserine (on D-serine) at doses relevant to those used as adjuncts in schizophrenia clinical trials [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] provides evidence of the likely common PFC neurochemical mechanisms involved in their actions.</p>
</sec>
<sec id="Sec24">
<title>Reversal of Scopolamine-Impaired Social Recognition and Time Delay Deficit in Novel Object Recognition</title>
<p id="Par38">Scopolamine reproducibly impaired social recognition memory, and this was reversed (in a dose-related manner) by at least two doses of the glycine modulatory site agonists glycine and D-serine, partial agonists D-cycloserine and S18841, and the GlyT1 inhibitors sarcosine and ORG24598. Although the pathological relevance of scopolamine as a cognitive disruptor can be questioned, it has been used as a translational tool to investigate GlyT1 inhibitors in primates and man [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>].</p>
<p id="Par39">All compounds also reduced a time-delay impairment of NOR that was dose-related for glycine, D-serine sarcosine and S18841. These pro-cognitive effects are consistent with previous studies. D-serine and NFPS improved performance in time-delay impairment of social recognition [<xref ref-type="bibr" rid="CR84">84</xref>]. Spontaneous NOR in mice and place recognition in rats and mice was enhanced by D-cycloserine [<xref ref-type="bibr" rid="CR85">85</xref>–<xref ref-type="bibr" rid="CR87">87</xref>]. Supporting the current data that sarcosine and ORG24598 attenuated natural forgetting in NOR performance, glycine reuptake inhibitors NFPS [<xref ref-type="bibr" rid="CR84">84</xref>] TASP0315003 [<xref ref-type="bibr" rid="CR88">88</xref>] and sarcosine all improved NOR and NMDA antagonist-impaired social recognition.</p>
</sec>
<sec id="Sec25">
<title>Involvement of the NMDA Receptor and PFC in S18841-Induced NOR Improvement</title>
<p id="Par40">In this study, reversal of the time-delay-induced impairment of NOR by acute S18841 was prevented by pre-treatment with the glycine site antagonist, L701,324, and the NDMA receptor antagonist, CPP, suggesting that NMDA receptor activation is required for the action of S18841. Consistent with this proposal, D-serine reversed the NOR impairment produced by the NMDA antagonists, MK-801 [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR89">89</xref>] or PCP [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. In primates, D-cycloserine improved performance in a variable delayed response task in the MPTP model of Parkinsonism [<xref ref-type="bibr" rid="CR91">91</xref>] and reversed impairments in a visual delay nonmatching-to-sample task caused by glycine site or NMDA receptor antagonism [<xref ref-type="bibr" rid="CR92">92</xref>]. Similarly, the partial glycine site agonist, GLYX-13 (Rapastinel), restored a PCP-induced NOR impairment [<xref ref-type="bibr" rid="CR93">93</xref>]. Both sarcosine and the glycine reuptake inhibitor (R)-(N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]) reversed an NMDA antagonist-induced impairment of NOR in rats and mice [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>] congruent with the proposal that glycine-induced enhancement of NMDA receptor function mediates the reported pro-cognitive effects.</p>
<p id="Par41">Bilateral microinjection of S18841 into the PFC (but not the striatum) dose-relatedly reversed intertrial delay-impaired NOR. However, the role of the PFC in NOR is complex, such that dopamine D<sub>2</sub> and D<sub>3</sub> receptor drugs have opposite effects on performance when injected into the PFC [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. Furthermore, D-cycloserine injection into the prelimbic cortex reversed scopolamine-induced amnesia in two olfactory (odour discrimination and food preference) tasks [<xref ref-type="bibr" rid="CR95">95</xref>], suggesting that the cortex may be a target for the observed reversal of muscarinic attenuation of social recognition reported herein. Of note, serine racemase knockout (SR−/−) mice develop neurons with reduced complexity, length and spine density of apical dendrites in the medial PFC and show impaired NOR [<xref ref-type="bibr" rid="CR96">96</xref>].</p>
</sec>
<sec id="Sec26">
<title>Restoration of Cognitive Performance but Not of Locomotor Activity by S18841 in Isolation-Reared Rats</title>
<p id="Par42">Rats reared in isolation took longer to habituate to a novel environment, but this hyperactivity, thought to reflect a mesolimbic hyperdopaminergic state analogous to that in psychosis [<xref ref-type="bibr" rid="CR97">97</xref>], was unaffected by S18841. Current antipsychotics reverse the isolation-induced hyperactivity, at least in part, through antagonism of dopamine D<sub>2</sub> receptors [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. Glycine site ligands do not possess D<sub>2</sub> affinity but may exert antipsychotic properties by a contrasting mechanism or enhance the clinical actions of antipsychotic drugs (although they have never actually been tested alone in patients).</p>
<p id="Par43">Consistent with previous studies [<xref ref-type="bibr" rid="CR44">44</xref>–<xref ref-type="bibr" rid="CR47">47</xref>], isolates showed a marked NOR deficit that was reversed by S18841, suggesting that glycine site agonists can reduce premature forgetting in this neurodevelopmental model of schizophrenia. Only one study has examined the effect of a glycine modulatory compound in isolation-reared rats. D-Cycloserine reversed a deficit in retention in a visual discrimination task [<xref ref-type="bibr" rid="CR99">99</xref>]. In the present CFR task, social isolation reduced contextual freezing 24 h post-conditioning and when the cue was presented 48 h post-training, consistent with impaired associative memory reported previously [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. S18841 given prior to conditioning attenuated the isolation-induced reduction in contextual freezing. Interestingly, the contextual memory phase of this task in rats is NMDA receptor dependent, being attenuated by MK-801 [<xref ref-type="bibr" rid="CR66">66</xref>], consistent with the current hypothesised mechanism of S18841.</p>
</sec>
<sec id="Sec27">
<title>General Discussion and Broader-Clinical Relevance of the Present Observations</title>
<p id="Par44">As a note of caution both social recognition and NOR tasks rely on spontaneous preference for novelty and their predictive validity to cognitive impairment in schizophrenia requires further confirmation [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>]. For instance, drugs with different pharmacological mechanisms, such as α7-nicotinic agonists and 5-HT<sub>6</sub> receptor antagonists produced much smaller improvements in cognition in schizophrenia clinical trials than would have been predicted from preclinical data, even in studies using disease models rather than normal animals. Nonetheless, in our hands, selective dopamine D<sub>2</sub> receptor antagonists impair social novelty discrimination and NOR [<xref ref-type="bibr" rid="CR54">54</xref>] consistent with the lack of effect or worsening of cognition seen with current antipsychotics in patients with schizophrenia, while the dopamine partial agonist cariprazine reversed the isolation-rearing induced impairment in NOR [<xref ref-type="bibr" rid="CR49">49</xref>].</p>
<p id="Par45">Taken together, this study provides extensive, consistent complimentary and neurochemical evidence that pharmacological modulation of glycine site activity on NMDA receptors can improve cognitive dysfunction in rats, but similar robust positive observations have not been reported in schizophrenia trials using glycine site agonists [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Poor translation may result from desensitisation of the glycine site as seen with repeated D-cycloserine [<xref ref-type="bibr" rid="CR102">102</xref>], producing NMDA receptor internalisation [<xref ref-type="bibr" rid="CR103">103</xref>] which might not occur with acute administration used in most animal studies. <italic>Second</italic>, the glycine full and partial agonists appear to have differential affinity for the different NMDA receptor subunit compositions found at pre- and post-synaptic sites in the cortex [<xref ref-type="bibr" rid="CR104">104</xref>] that could affect their relative clinical effectiveness. <italic>Thirdly</italic>, the ability of glycine site agonists to facilitate symptom improvement may be impeded by antipsychotics with muscarinic antagonism, such as clozapine and other atypicals, by opposing any pro-cognitive actions [<xref ref-type="bibr" rid="CR94">94</xref>]. Interestingly, D-serine, D-cycloserine and sodium benzoate all improve haloperidol-induced bradykinesia in the rat by elevating nigrostriatal dopamine release, suggesting that they may also reduce antipsychotic-induced extrapyramidal side effects [<xref ref-type="bibr" rid="CR105">105</xref>]. Furthermore, they might be useful in the prodromal phase to alleviate pre-diagnostic symptoms and, by improving social cognition and social integration, decrease risk of transition to psychosis [<xref ref-type="bibr" rid="CR27">27</xref>–<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p>
<p id="Par46">The present observations provide a framework to examine other agents, including novel glycine site agonists, like Rapastinel [<xref ref-type="bibr" rid="CR93">93</xref>] and NSX-2925 [<xref ref-type="bibr" rid="CR14">14</xref>], the uptake inhibitors TASP0315003 [<xref ref-type="bibr" rid="CR88">88</xref>] and bitopertin [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], D-amino acid oxidases inhibitors like sodium benzoate [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR106">106</xref>], and inhibitors of kynurenine aminotransferase II all of which modify PFC glutamatergic signalling [<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. Furthermore, it would be interesting to study agents acting at the neuronal alanine-serine-cysteine-1 transporter which is implicated in the control of extracellular D-serine and glycine [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR109">109</xref>]. Finally, one might compare the actions of BMS-466442, which suppresses D-serine uptake [<xref ref-type="bibr" rid="CR110">110</xref>], with those of LuAE00527 which prevents D-serine release [<xref ref-type="bibr" rid="CR79">79</xref>].</p>
<p id="Par47">Although most research focusses on these agents enhancing cognition in psychiatric disorders [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR111">111</xref>], current findings are pertinent to disorders, like Alzheimer’s disease [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>], where plasma D-amino acid oxidase levels correlate with cognitive decline [<xref ref-type="bibr" rid="CR114">114</xref>] but other work suggests that elevated brain D-serine occurs in Alzheimer’s [<xref ref-type="bibr" rid="CR112">112</xref>]. Furthermore, akin to the fast antidepressant actions of ketamine, glycine site partial agonists like Rapastinel may exert antidepressant effects via enhanced mTOR and BDNF signalling [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Intriguingly, the major metabolites of ketamine are D-serine racemase inhibitors [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>], providing a direct link to the present work. In addition, D-cycloserine and other glycine site ligands may improve social cognition in ASDs and genetically related Rett syndrome [<xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR116">116</xref>]. Other indications under consideration include drug abuse [<xref ref-type="bibr" rid="CR117">117</xref>], amyotrophic lateral sclerosis [<xref ref-type="bibr" rid="CR22">22</xref>], chronic pain [<xref ref-type="bibr" rid="CR118">118</xref>] and facilitation of psychosocial-cognitive behavioural therapies for anxiety disorders [<xref ref-type="bibr" rid="CR119">119</xref>].</p>
</sec>
</sec>
<sec sec-type="supplementary-material">
<title>Electronic Supplementary Material</title>
<sec id="Sec28">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12035_2020_1875_MOESM1_ESM.pdf"><label>ESM 1</label><caption><p>(PDF 137 kb)</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>
<bold>Publisher’s Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>We thank Clare Spicer for technical assistance. Studies were designed by KCFF and MJM. Experimental work was undertaken at the University of Nottingham by DJGW and KCFF and at Servier by AG, RB, DS, AD and J-MR. The first draft of the manuscript was produced by DJGW, KCFF and MJM, and all authors contributed to production of the final version.</p>
</ack>
<notes>
<title>Compliance with Ethical Standards</title>
<notes>
<title>Ethical Approval</title>
<p id="Par48">All procedures performed in studies involving animals were performed in accordance with the ethical standards of the University of Nottinhgam, the Animals (Scientific Procedures) Act, 1986 and ARRIVE guidelines and with approval of University of Nottingham Local Ethical Committee (behavior) or EU guidelines (microdialysis).</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflict of Interest</title>
<p id="Par49">We declare that, except for income received from their primary employer, no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional service, and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest. The contribution to this work made by DJGW and KCFF was financially supported by Servier. MJM, AG, RB, DS, AD and J-MR are employed by Servier.</p>
</notes>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Moaddel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Georgiou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fischell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Elmer</surname>
<given-names>GI</given-names>
</name>
<name>
<surname>Alkondon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pribut</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Dossou</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>XP</given-names>
</name>
<name>
<surname>Mayo</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Wainer</surname>
<given-names>IW</given-names>
</name>
<name>
<surname>Albuquerque</surname>
<given-names>EX</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Zarate</surname>
<given-names>CA</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Gould</surname>
<given-names>TD</given-names>
</name>
</person-group>
<article-title>NMDAR inhibition-independent antidepressant actions of ketamine metabolites</article-title>
<source/>Nature
          <year>2016</year>
<volume>533</volume>
<issue>7604</issue>
<fpage>481</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="doi">10.1038/nature17998</pub-id>
<pub-id pub-id-type="pmid">27144355</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Skiteva</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Svenningsson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chergui</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit</article-title>
<source/>Mol Psychiatry
          <year>2018</year>
<volume>23</volume>
<issue>10</issue>
<fpage>2066</fpage>
<lpage>2077</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2017.239</pub-id>
<pub-id pub-id-type="pmid">29158578</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cavalleri</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Merlo Pich</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Chiamulera</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kunath</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Spano</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Collo</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling</article-title>
<source/>Mol Psychiatry
          <year>2018</year>
<volume>23</volume>
<issue>4</issue>
<fpage>812</fpage>
<lpage>823</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2017.241</pub-id>
<pub-id pub-id-type="pmid">29158584</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moghaddam</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Javitt</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment</article-title>
<source/>Neuropsychopharmacology
          <year>2012</year>
<volume>37</volume>
<issue>1</issue>
<fpage>4</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2011.181</pub-id>
<pub-id pub-id-type="pmid">21956446</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collingridge</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Volianskis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bannister</surname>
<given-names>N</given-names>
</name>
<name>
<surname>France</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hanna</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mercier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tidball</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Irvine</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Monaghan</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Bortolotto</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Molnar</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lodge</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jane</surname>
<given-names>DE</given-names>
</name>
</person-group>
<article-title>The NMDA receptor as a target for cognitive enhancement</article-title>
<source/>Neuropharmacology
          <year>2013</year>
<volume>64</volume>
<fpage>13</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.06.051</pub-id>
<pub-id pub-id-type="pmid">22796429</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fossat</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Turpin</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Sacchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dulong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rivet</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Sweedler</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Pollegioni</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Oliet</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Mothet</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex</article-title>
<source/>Cereb Cortex
          <year>2012</year>
<volume>22</volume>
<issue>3</issue>
<fpage>595</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/bhr130</pub-id>
<pub-id pub-id-type="pmid">21690263</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lench</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Massey</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Pollegioni</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Woodhall</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Astroglial d-serine is the endogenous co-agonist at the presynaptic NMDA receptor in rat entorhinal cortex</article-title>
<source/>Neuropharmacology
          <year>2014</year>
<volume>83</volume>
<fpage>118</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.04.004</pub-id>
<pub-id pub-id-type="pmid">24747728</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Artoul</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Kolodney</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Radzishevsky</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dikopoltsev</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Foltyn</surname>
<given-names>VN</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Billard</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Wolosker</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Neuronal D-serine and glycine release via the Asc-1 transporter regulates NMDA receptor-dependent synaptic activity</article-title>
<source/>J Neurosci
          <year>2013</year>
<volume>33</volume>
<issue>8</issue>
<fpage>3533</fpage>
<lpage>3544</lpage>
<pub-id pub-id-type="doi">10.1523/jneurosci.3836-12.2013</pub-id>
<pub-id pub-id-type="pmid">23426681</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ju</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The involvement of N-methyl-D-aspartate receptor (NMDAR) subunit NR1 in the pathophysiology of schizophrenia</article-title>
<source/>Acta Biochim Biophys Sin Shanghai
          <year>2016</year>
<volume>48</volume>
<issue>3</issue>
<fpage>209</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1093/abbs/gmv135</pub-id>
<pub-id pub-id-type="pmid">26837414</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balu</surname>
<given-names>DT</given-names>
</name>
</person-group>
<article-title>The NMDA receptor and schizophrenia: From pathophysiology to treatment</article-title>
<source/>Adv Pharmacol (San Diego, Calif)
          <year>2016</year>
<volume>76</volume>
<fpage>351</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="doi">10.1016/bs.apha.2016.01.006</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvey</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Yee</surname>
<given-names>BK</given-names>
</name>
</person-group>
<article-title>Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain</article-title>
<source/>Nat Rev Drug Discov
          <year>2013</year>
<volume>12</volume>
<issue>11</issue>
<fpage>866</fpage>
<lpage>885</lpage>
<pub-id pub-id-type="doi">10.1038/nrd3893</pub-id>
<pub-id pub-id-type="pmid">24172334</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<mixed-citation publication-type="other">Lin CY, Liang SY, Chang YC, Ting SY, Kao CL, Wu YH, Tsai GE, Lane HY (2017) Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry 18(5):357–368. 10.3109/15622975.2015.1117654</mixed-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burgdorf</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>XL</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Balster</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Leander</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Stanton</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Kroes</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Moskal</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects</article-title>
<source/>Neuropsychopharmacology
          <year>2013</year>
<volume>38</volume>
<issue>5</issue>
<fpage>729</fpage>
<lpage>742</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2012.246</pub-id>
<pub-id pub-id-type="pmid">23303054</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Houck</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>XL</given-names>
</name>
<name>
<surname>Cearley</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Kroes</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Stanton</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Burgdorf</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Moskal</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>NYX-2925 is a novel NMDA receptor-specific spirocyclic-beta-lactam that modulates synaptic plasticity processes associated with learning and memory</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2018</year>
<volume>21</volume>
<issue>3</issue>
<fpage>242</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1093/ijnp/pyx096</pub-id>
<pub-id pub-id-type="pmid">29099938</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cordi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lacoste</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Audinot</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Millan</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Design, synthesis and structure-activity relationships of novel strychnine-insensitive glycine receptor ligands</article-title>
<source/>Bioorg Med Chem Lett
          <year>1999</year>
<volume>9</volume>
<issue>10</issue>
<fpage>1409</fpage>
<lpage>1414</lpage>
<pub-id pub-id-type="doi">10.1016/S0960-894X(99)00194-8</pub-id>
<pub-id pub-id-type="pmid">10360746</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balu</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Coyle</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond</article-title>
<source/>Curr Opin Pharmacol
          <year>2015</year>
<volume>20</volume>
<fpage>109</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="doi">10.1016/j.coph.2014.12.004</pub-id>
<pub-id pub-id-type="pmid">25540902</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goff</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>D-cycloserine in schizophrenia: New strategies for improving clinical outcomes by enhancing plasticity</article-title>
<source/>Curr Neuropharmacol
          <year>2017</year>
<volume>15</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.2174/1570159X14666160225154812</pub-id>
<pub-id pub-id-type="pmid">26915421</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwarcz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rassoulpour</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>HQ</given-names>
</name>
<name>
<surname>Medoff</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tamminga</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>Increased cortical kynurenate content in schizophrenia</article-title>
<source/>Biol Psychiatry
          <year>2001</year>
<volume>50</volume>
<issue>7</issue>
<fpage>521</fpage>
<lpage>530</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(01)01078-2</pub-id>
<pub-id pub-id-type="pmid">11600105</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bendikov</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nadri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Amar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Panizzutti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>De Miranda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wolosker</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Agam</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia</article-title>
<source/>Schizophr Res
          <year>2007</year>
<volume>90</volume>
<issue>1–3</issue>
<fpage>41</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2006.10.010</pub-id>
<pub-id pub-id-type="pmid">17156977</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brouwer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Luykx</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>van Boxmeer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>NMDA-receptor coagonists in serum, plasma, and cerebrospinal fluid of schizophrenia patients: A meta-analysis of case-control studies</article-title>
<source/>Neurosci Biobehav Rev
          <year>2013</year>
<volume>37</volume>
<issue>8</issue>
<fpage>1587</fpage>
<lpage>1596</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2013.06.007</pub-id>
<pub-id pub-id-type="pmid">23792047</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neeman</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Blanaru</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bloch</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kremer</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ermilov</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Javitt</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Heresco-Levy</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type</article-title>
<source/>Am J Psychiatry
          <year>2005</year>
<volume>162</volume>
<issue>9</issue>
<fpage>1738</fpage>
<lpage>1740</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.162.9.1738</pub-id>
<pub-id pub-id-type="pmid">16135636</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molla</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Competitive inhibitors unveil structure/function relationships in human D-amino acid oxidase</article-title>
<source/>Front Mol Biosci
          <year>2017</year>
<volume>4</volume>
<fpage>80</fpage>
<pub-id pub-id-type="doi">10.3389/fmolb.2017.00080</pub-id>
<pub-id pub-id-type="pmid">29250527</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santini</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Pierantoni</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Gerlini</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Iorio</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Olabinjo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Giovane</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Di Domenico</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sogos</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Glix 13, a new drug acting on glutamatergic pathways in children and animal models of autism spectrum disorders</article-title>
<source/>Biomed Res Int
          <year>2014</year>
<volume>2014</volume>
<fpage>234295</fpage>
<pub-id pub-id-type="doi">10.1155/2014/234295</pub-id>
<pub-id pub-id-type="pmid">24605324</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>HC</given-names>
</name>
</person-group>
<article-title>D-Cycloserine ameliorates autism-like deficits by removing GluA2-containing AMPA receptors in a valproic acid-induced rat model</article-title>
<source/>Mol Neurobiol
          <year>2018</year>
<volume>55</volume>
<issue>6</issue>
<fpage>4811</fpage>
<lpage>4824</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-017-0685-1</pub-id>
<pub-id pub-id-type="pmid">28733898</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Urbano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Okwara</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Manser</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Herndon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Deutsch</surname>
<given-names>SI</given-names>
</name>
</person-group>
<article-title>A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder</article-title>
<source/>Clin Neuropharmacol
          <year>2014</year>
<volume>37</volume>
<issue>3</issue>
<fpage>69</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1097/WNF.0000000000000033</pub-id>
<pub-id pub-id-type="pmid">24824660</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Keefe</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Plitman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Caravaggio</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mimura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Graff-Guerrero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Uchida</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Effects of glutamate positive modulators on cognitive deficits in schizophrenia: A systematic review and meta-analysis of double-blind randomized controlled trials</article-title>
<source/>Mol Psychiatry
          <year>2015</year>
<volume>20</volume>
<issue>10</issue>
<fpage>1151</fpage>
<lpage>1160</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2015.68</pub-id>
<pub-id pub-id-type="pmid">26077694</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devoe</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Addington</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Negative symptom interventions in youth at risk of psychosis: A systematic review and network meta-analysis</article-title>
<source/>Schizophr Bull
          <year>2018</year>
<volume>44</volume>
<issue>4</issue>
<fpage>807</fpage>
<lpage>823</lpage>
<pub-id pub-id-type="doi">10.1093/schbul/sbx139</pub-id>
<pub-id pub-id-type="pmid">29069511</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Andrieux</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bartzokis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cadenhead</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dazzan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fusar-Poli</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gallinat</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Giedd</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grayson</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Heinrichs</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Krebs</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Leboyer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Marin</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Marin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Meyer-Lindenberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McGorry</surname>
<given-names>P</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Spedding</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Uhlhaas</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vaccarino</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wahlestedt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Weinberger</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Altering the course of schizophrenia: Progress and perspectives</article-title>
<source/>Nat Rev Drug Discov
          <year>2016</year>
<volume>15</volume>
<issue>7</issue>
<fpage>485</fpage>
<lpage>515</lpage>
<pub-id pub-id-type="doi">10.1038/nrd.2016.28</pub-id>
<pub-id pub-id-type="pmid">26939910</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woods</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Hawkins</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Saksa</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>D'Souza</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Pearlson</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Javitt</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>McGlashan</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Krystal</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies</article-title>
<source/>Eur Neuropsychopharmacol
          <year>2013</year>
<volume>23</volume>
<issue>8</issue>
<fpage>931</fpage>
<lpage>940</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2012.09.008</pub-id>
<pub-id pub-id-type="pmid">23089076</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alberati</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Moreau</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Lengyel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mory</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pinard</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Knoflach</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schlotterbeck</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hainzl</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wettstein</surname>
<given-names>JG</given-names>
</name>
</person-group>
<article-title>Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia</article-title>
<source/>Neuropharmacology
          <year>2012</year>
<volume>62</volume>
<issue>2</issue>
<fpage>1152</fpage>
<lpage>1161</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.11.008</pub-id>
<pub-id pub-id-type="pmid">22138164</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kopec</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Flood</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Gasior</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McKenna</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Zuvich</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Salvino</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Durkin</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Ator</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice</article-title>
<source/>Biochem Pharmacol
          <year>2010</year>
<volume>80</volume>
<issue>9</issue>
<fpage>1407</fpage>
<lpage>1417</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2010.07.004</pub-id>
<pub-id pub-id-type="pmid">20637735</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yarimizu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Morita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aota</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Saita</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Doihara</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yamaji</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Matsuoka</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazol e), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease</article-title>
<source/>Eur J Pharmacol
          <year>2012</year>
<volume>685</volume>
<issue>1–3</issue>
<fpage>59</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2012.04.013</pub-id>
<pub-id pub-id-type="pmid">22542656</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Kamenski</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Higa</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Light</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Geyer</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>GlyT-1 inhibition attenuates attentional but not learning or motivational deficits of the Sp4 hypomorphic mouse model relevant to psychiatric disorders</article-title>
<source/>Neuropsychopharmacology
          <year>2015</year>
<volume>40</volume>
<issue>12</issue>
<fpage>2715</fpage>
<lpage>2726</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2015.120</pub-id>
<pub-id pub-id-type="pmid">25907107</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Umbricht</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Alberati</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Martin-Facklam</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Youssef</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Ostland</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Knoflach</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dorflinger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wettstein</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Bausch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Garibaldi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Santarelli</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study</article-title>
<source/>JAMA Psychiatry
          <year>2014</year>
<volume>71</volume>
<issue>6</issue>
<fpage>637</fpage>
<lpage>646</lpage>
<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.163</pub-id>
<pub-id pub-id-type="pmid">24696094</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dubroqua</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yee</surname>
<given-names>BK</given-names>
</name>
</person-group>
<article-title>Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?</article-title>
<source/>Curr Pharm Design
          <year>2015</year>
<volume>21</volume>
<issue>26</issue>
<fpage>3771</fpage>
<lpage>3787</lpage>
<pub-id pub-id-type="doi">10.2174/1381612821666150724100952</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bugarski-Kirola</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sameljak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Blaettler</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Millar</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Marques</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Garibaldi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kapur</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: Results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme</article-title>
<source/>Lancet Psychiatry
          <year>2016</year>
<volume>3</volume>
<issue>12</issue>
<fpage>1115</fpage>
<lpage>1128</lpage>
<pub-id pub-id-type="doi">10.1016/s2215-0366(16)30344-3</pub-id>
<pub-id pub-id-type="pmid">27816567</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Rivet</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Gobert</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders</article-title>
<source/>J Psychopharmacol
          <year>2016</year>
<volume>30</volume>
<issue>11</issue>
<fpage>1099</fpage>
<lpage>1128</lpage>
<pub-id pub-id-type="doi">10.1177/0269881116672342</pub-id>
<pub-id pub-id-type="pmid">27756833</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Risbrough</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Marston</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Geyer</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia</article-title>
<source/>Pharmacol Ther
          <year>2009</year>
<volume>122</volume>
<issue>2</issue>
<fpage>150</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2009.02.004</pub-id>
<pub-id pub-id-type="pmid">19269307</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bales</surname>
<given-names>KL</given-names>
</name>
</person-group>
<article-title>Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: The CNTRICS initiative</article-title>
<source/>Neurosci Biobehav Rev
          <year>2013</year>
<volume>37</volume>
<issue>9</issue>
<fpage>2166</fpage>
<lpage>2180</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2013.09.012</pub-id>
<pub-id pub-id-type="pmid">24090822</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fone</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Porkess</surname>
<given-names>MV</given-names>
</name>
</person-group>
<article-title>Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders</article-title>
<source/>Neurosci Biobehav Rev
          <year>2008</year>
<volume>32</volume>
<issue>6</issue>
<fpage>1087</fpage>
<lpage>1102</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2008.03.003</pub-id>
<pub-id pub-id-type="pmid">18423591</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KC</given-names>
</name>
</person-group>
<article-title>Animal models of schizophrenia</article-title>
<source/>Br J Pharmacol
          <year>2011</year>
<volume>164</volume>
<issue>4</issue>
<fpage>1162</fpage>
<lpage>1194</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01386.x</pub-id>
<pub-id pub-id-type="pmid">21449915</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabricius</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Helboe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Steiniger-Brach</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fink-Jensen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pakkenberg</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Stereological brain volume changes in post-weaned socially isolated rats</article-title>
<source/>Brain Res
          <year>2010</year>
<volume>1345</volume>
<fpage>233</fpage>
<lpage>239</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2010.05.040</pub-id>
<pub-id pub-id-type="pmid">20546705</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schubert</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Porkess</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Dashdorj</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KCF</given-names>
</name>
<name>
<surname>Auer</surname>
<given-names>DP</given-names>
</name>
</person-group>
<article-title>Effects of social isolation rearing on the limbic brain: A combined behavioral and magnetic resonance imaging volumetry study in rats</article-title>
<source/>Neuroscience
          <year>2009</year>
<volume>159</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.12.019</pub-id>
<pub-id pub-id-type="pmid">19141315</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<mixed-citation publication-type="other">Gaskin PL, Toledo-Rodriguez M, Alexander SP, Fone KC (2016) Down-regulation of hippocampal genes regulating dopaminergic, GABAergic, and glutamatergic function following combined neonatal phencyclidine and post-weaning social isolation of rats as a neurodevelopmental model for schizophrenia. Int J Neuropsychopharmacol 19(11). 10.1093/ijnp/pyw062</mixed-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Auer</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KC</given-names>
</name>
</person-group>
<article-title>The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat</article-title>
<source/>Psychopharmacology
          <year>2011</year>
<volume>214</volume>
<issue>1</issue>
<fpage>269</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-010-1931-7</pub-id>
<pub-id pub-id-type="pmid">20607219</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McIntosh</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Steward</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KC</given-names>
</name>
</person-group>
<article-title>The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats</article-title>
<source/>Psychopharmacology
          <year>2013</year>
<volume>228</volume>
<issue>1</issue>
<fpage>31</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-013-3011-2</pub-id>
<pub-id pub-id-type="pmid">23397053</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meffre</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chaumont-Dubel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>la Cour</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Loiseau</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>DJG</given-names>
</name>
<name>
<surname>Dekeyne</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Seveno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rivet</surname>
<given-names>J-M</given-names>
</name>
<name>
<surname>Gaven</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Deleris</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Herve</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KCF</given-names>
</name>
<name>
<surname>Bockaert</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Marin</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>5-HT6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia</article-title>
<source/>EMBO Mol Med
          <year>2012</year>
<volume>4</volume>
<issue>10</issue>
<fpage>1043</fpage>
<lpage>1056</lpage>
<pub-id pub-id-type="doi">10.1002/emmm.201201410</pub-id>
<pub-id pub-id-type="pmid">23027611</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaskin</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KC</given-names>
</name>
</person-group>
<article-title>Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat</article-title>
<source/>Psychopharmacology
          <year>2014</year>
<volume>231</volume>
<issue>12</issue>
<fpage>2533</fpage>
<lpage>2545</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-013-3424-y</pub-id>
<pub-id pub-id-type="pmid">24402141</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watson</surname>
<given-names>DJG</given-names>
</name>
<name>
<surname>King</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Gyertyan</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kiss</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Adham</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KCF</given-names>
</name>
</person-group>
<article-title>The dopamine D(3)-preferring D(2)/D(3) dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia</article-title>
<source/>Eur Neuropsychopharmacol
          <year>2016</year>
<volume>26</volume>
<issue>2</issue>
<fpage>208</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2015.12.020</pub-id>
<pub-id pub-id-type="pmid">26723167</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Paxinos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>C</given-names>
</name>
</person-group>
<source/>The rat brain in Stereotaxis coordinates, 4th edition
          <year>1998</year>
<edition>4</edition>
<publisher-loc>London</publisher-loc>
<publisher-name>Academic Press</publisher-name>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gobert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rivet</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Billiras</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Simultaneous quantification of D- vs. L-serine, taurine, kynurenate, phosphoethanolamine and diverse amino acids in frontocortical dialysates of freely-moving rats: Differential modulation by N-methyl-D-aspartate (NMDA) and other pharmacological agents</article-title>
<source/>J Neurosci Methods
          <year>2011</year>
<volume>202</volume>
<issue>2</issue>
<fpage>143</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneumeth.2011.08.040</pub-id>
<pub-id pub-id-type="pmid">21920385</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Terranova</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Worms</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bluthe</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Dantzer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Biziere</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Specific modulation of social memory in rats by cholinomimetic and nootropic drugs, by benzodiazepine inverse agonists, but not by psychostimulants</article-title>
<source/>Psychopharmacology
          <year>1989</year>
<volume>97</volume>
<issue>2</issue>
<fpage>262</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="doi">10.1007/BF00442261</pub-id>
<pub-id pub-id-type="pmid">2567026</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nuechterlein</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Einat</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Distinguishing separable domains of cognition in human and animal studies: What separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference</article-title>
<source/>Schizophr Bull
          <year>2005</year>
<volume>31</volume>
<issue>4</issue>
<fpage>870</fpage>
<lpage>874</lpage>
<pub-id pub-id-type="doi">10.1093/schbul/sbi047</pub-id>
<pub-id pub-id-type="pmid">16150960</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watson</surname>
<given-names>DJG</given-names>
</name>
<name>
<surname>Loiseau</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ingallinesi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Marsden</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KCF</given-names>
</name>
</person-group>
<article-title>Selective blockade of dopamine D-3 receptors enhances while D-2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: A key role for the prefrontal cortex</article-title>
<source/>Neuropsychopharmacology
          <year>2012</year>
<volume>37</volume>
<issue>3</issue>
<fpage>770</fpage>
<lpage>786</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2011.254</pub-id>
<pub-id pub-id-type="pmid">22030711</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loiseau</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Blockade of dopamine D-3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: Similar actions of D-1 receptor agonists, but not of D-2 antagonists</article-title>
<source/>Eur Neuropsychopharmacol
          <year>2009</year>
<volume>19</volume>
<issue>1</issue>
<fpage>23</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2008.07.012</pub-id>
<pub-id pub-id-type="pmid">18793829</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>King</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Seeman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Marsden</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KCF</given-names>
</name>
</person-group>
<article-title>Increased dopamine D2(high) receptors in rats reared in social isolation</article-title>
<source/>Synapse
          <year>2009</year>
<volume>63</volume>
<issue>6</issue>
<fpage>476</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="doi">10.1002/syn.20624</pub-id>
<pub-id pub-id-type="pmid">19217027</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watson</surname>
<given-names>DJG</given-names>
</name>
<name>
<surname>Marsden</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KCF</given-names>
</name>
</person-group>
<article-title>Blockade of dopamine D-3 but not D-2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: Implications for schizophrenia and its treatment</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2012</year>
<volume>15</volume>
<issue>4</issue>
<fpage>471</fpage>
<lpage>484</lpage>
<pub-id pub-id-type="doi">10.1017/s1461145711000435</pub-id>
<pub-id pub-id-type="pmid">21414250</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ennaceur</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Delacour</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data</article-title>
<source/>Behav Brain Res
          <year>1988</year>
<volume>31</volume>
<issue>1</issue>
<fpage>47</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1016/0166-4328(88)90157-X</pub-id>
<pub-id pub-id-type="pmid">3228475</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajagopal</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Massey</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oyamada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>HY</given-names>
</name>
</person-group>
<article-title>The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia</article-title>
<source/>Curr Pharm Design
          <year>2014</year>
<volume>20</volume>
<issue>31</issue>
<fpage>5104</fpage>
<lpage>5114</lpage>
<pub-id pub-id-type="doi">10.2174/1381612819666131216114240</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sivakumaran</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Callan</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Ainge</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>O'Connor</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>The discrimination ratio derived from novel object recognition tasks as a measure of recognition memory sensitivity, not bias</article-title>
<source/>Sci Rep
          <year>2018</year>
<volume>8</volume>
<issue>1</issue>
<fpage>11579</fpage>
<lpage>11512</lpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-30030-7</pub-id>
<pub-id pub-id-type="pmid">30069031</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>King</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Sleight</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Woolley</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Topham</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Marsden</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KCF</given-names>
</name>
</person-group>
<article-title>5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation - an effect sensitive to NMDA receptor antagonism</article-title>
<source/>Neuropharmacology
          <year>2004</year>
<volume>47</volume>
<issue>2</issue>
<fpage>195</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2004.03.012</pub-id>
<pub-id pub-id-type="pmid">15223298</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Buccafusco</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Loiseau</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>DJG</given-names>
</name>
<name>
<surname>Decamp</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KCF</given-names>
</name>
<name>
<surname>Thomasson-Perret</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mocaer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>The dopamine D(3) receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2010</year>
<volume>13</volume>
<issue>8</issue>
<fpage>1035</fpage>
<lpage>1051</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145710000775</pub-id>
<pub-id pub-id-type="pmid">20663270</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anagnostaras</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Maren</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sage</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Goodrich</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fanselow</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Scopolamine and Pavlovian fear conditioning in rats: Dose-effect analysis</article-title>
<source/>Neuropsychopharmacology
          <year>1999</year>
<volume>21</volume>
<issue>6</issue>
<fpage>731</fpage>
<lpage>744</lpage>
<pub-id pub-id-type="doi">10.1016/S0893-133X(99)00083-4</pub-id>
<pub-id pub-id-type="pmid">10633479</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herbener</surname>
<given-names>ES</given-names>
</name>
</person-group>
<article-title>Impairment in long-term retention of preference conditioning in schizophrenia</article-title>
<source/>Biol Psychiatry
          <year>2009</year>
<volume>65</volume>
<issue>12</issue>
<fpage>1086</fpage>
<lpage>1090</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2009.01.020</pub-id>
<pub-id pub-id-type="pmid">19246031</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lonsdorf</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Richter</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Challenges of fear conditioning research in the age of RDoC</article-title>
<source/>Zeitschrift Fur Psychologie-J Psychol
          <year>2017</year>
<volume>225</volume>
<issue>3</issue>
<fpage>189</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="doi">10.1027/2151-2604/a000303</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woods</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Layfield</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KC</given-names>
</name>
</person-group>
<article-title>5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms</article-title>
<source/>Br J Pharmacol
          <year>2012</year>
<volume>167</volume>
<issue>2</issue>
<fpage>436</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.02022.x</pub-id>
<pub-id pub-id-type="pmid">22568655</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Depoortere</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dargazanli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Estenne-Bouhtou</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Coste</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lanneau</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Desvignes</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Poncelet</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heaulme</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Santucci</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Decobert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cudennec</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Voltz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Boulay</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Terranova</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Stemmelin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Roger</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Marabout</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sevrin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vige</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Biton</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Francon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Avenet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Oury-Donat</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Perrault</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Griebel</surname>
<given-names>G</given-names>
</name>
<name>
<surname>George</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Soubrie</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Scatton</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-I SSR504734, a potential new type of antipsychotic</article-title>
<source/>Neuropsychopharmacology
          <year>2005</year>
<volume>30</volume>
<issue>11</issue>
<fpage>1963</fpage>
<lpage>1985</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300772</pub-id>
<pub-id pub-id-type="pmid">15956994</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voehringer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fuertig</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ferger</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>A novel liquid chromatography/tandem mass spectrometry method for the quantification of glycine as biomarker in brain microdialysis and cerebrospinal fluid samples within 5min</article-title>
<source/>J Chromatogr B Anal Technol Biomed Life Sci
          <year>2013</year>
<volume>939</volume>
<fpage>92</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1016/j.jchromb.2013.09.011</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagy</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Marko</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zsilla</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Matyus</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pallagi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Szabo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Juranyi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Barkoczy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Levay</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Harsing</surname>
<given-names>LG</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<article-title>Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone</article-title>
<source/>Neurochem Res
          <year>2010</year>
<volume>35</volume>
<issue>12</issue>
<fpage>2096</fpage>
<lpage>2106</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-010-0241-0</pub-id>
<pub-id pub-id-type="pmid">20725779</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perry</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Falcone</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Fell</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Ryder</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Love</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Katner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Wade</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nomikos</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Phebus</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Cauvin</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Sandusky</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Merchant</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Svensson</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas</article-title>
<source/>Neuropharmacology
          <year>2008</year>
<volume>55</volume>
<issue>5</issue>
<fpage>743</fpage>
<lpage>754</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.06.016</pub-id>
<pub-id pub-id-type="pmid">18602930</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hofmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pizzagalli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Boetsch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Alberati</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ereshefsky</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jhee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Patat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boutouyrie-Dumont</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Martin-Facklam</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: Results of two proofs of mechanism studies in healthy volunteers</article-title>
<source/>Psychopharmacology
          <year>2016</year>
<volume>233</volume>
<issue>13</issue>
<fpage>2429</fpage>
<lpage>2439</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-016-4317-7</pub-id>
<pub-id pub-id-type="pmid">27178435</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin-Facklam</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pizzagalli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ostrowitzki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Raymont</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Brasic</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Parkar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Umbricht</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dannals</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Goldwater</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>Glycine transporter type 1 occupancy by bitopertin: A positron emission tomography study in healthy volunteers</article-title>
<source/>Neuropsychopharmacology
          <year>2013</year>
<volume>38</volume>
<issue>3</issue>
<fpage>504</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2012.212</pub-id>
<pub-id pub-id-type="pmid">23132267</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strzelecki</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Podgorski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaluzynska</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Stefanczyk</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kotlicka-Antczak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gmitrowicz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grzelak</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Adding sarcosine to antipsychotic treatment in patients with stable schizophrenia changes the concentrations of neuronal and glial metabolites in the left dorsolateral prefrontal cortex</article-title>
<source/>Int J Mol Sci
          <year>2015</year>
<volume>16</volume>
<issue>10</issue>
<fpage>24475</fpage>
<lpage>24489</lpage>
<pub-id pub-id-type="doi">10.3390/ijms161024475</pub-id>
<pub-id pub-id-type="pmid">26501260</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Javitt</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Glycine transport inhibitors in the treatment of schizophrenia</article-title>
<source/>Handb Exp Pharmacol
          <year>2012</year>
<volume>213</volume>
<fpage>367</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="doi">10.1007/978-3-642-25758-2_12</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strzelecki</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Szyburska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rabe-Jablonska</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Two grams of sarcosine in schizophrenia - is it too much? A potential role of glutamate-serotonin interaction</article-title>
<source/>Neuropsychiatr Dis Treat
          <year>2014</year>
<volume>10</volume>
<fpage>263</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="doi">10.2147/NDT.S54024</pub-id>
<pub-id pub-id-type="pmid">24523591</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bannai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nagao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Matsuzawa</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Oral administration of glycine increases extracellular serotonin but not dopamine in the prefrontal cortex of rats</article-title>
<source/>Psychiatry Clin Neurosci
          <year>2011</year>
<volume>65</volume>
<issue>2</issue>
<fpage>142</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="doi">10.1111/j.1440-1819.2010.02181.x</pub-id>
<pub-id pub-id-type="pmid">21414089</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Brocco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gobert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Joly</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bervoets</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rivet</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Newman-Tancredi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Audinot</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Maurel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: Importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat</article-title>
<source/>Eur J Neurosci
          <year>1999</year>
<volume>11</volume>
<issue>12</issue>
<fpage>4419</fpage>
<lpage>4432</lpage>
<pub-id pub-id-type="doi">10.1046/j.1460-9568.1999.00858.x</pub-id>
<pub-id pub-id-type="pmid">10594669</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishiwata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Umino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Involvement of neuronal and glial activities in control of the extracellular d-serine concentrations by the AMPA glutamate receptor in the mouse medial prefrontal cortex</article-title>
<source/>Neurochem Int
          <year>2018</year>
<volume>119</volume>
<fpage>120</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2017.09.009</pub-id>
<pub-id pub-id-type="pmid">28966065</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sason</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Billard</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Safory</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Neame</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zubedat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Foltyn</surname>
<given-names>VN</given-names>
</name>
<name>
<surname>Christoffersen</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Bundgaard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Thomsen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Avital</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>Wolosker</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Asc-1 transporter regulation of synaptic activity via the tonic release of d-serine in the forebrain</article-title>
<source/>Cereb Cortex
          <year>2017</year>
<volume>27</volume>
<issue>2</issue>
<fpage>1573</fpage>
<lpage>1587</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/bhv350</pub-id>
<pub-id pub-id-type="pmid">26796213</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujihira</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kanematsu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Umino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Selective increase in the extracellular D-serine contents by D-cycloserine in the rat medial frontal cortex</article-title>
<source/>Neurochem Int
          <year>2007</year>
<volume>51</volume>
<issue>2–4</issue>
<fpage>233</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2007.06.003</pub-id>
<pub-id pub-id-type="pmid">17662507</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Is D-cycloserine a prodrug for D-serine in the brain?</article-title>
<source/>Biol Psychiatry
          <year>2013</year>
<volume>73</volume>
<issue>12</issue>
<fpage>e33</fpage>
<lpage>e34</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2012.07.013</pub-id>
<pub-id pub-id-type="pmid">22877923</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eddins</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hamill</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Puri</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Vivian</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Sanabria-Bohorquez</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Uslaner</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey</article-title>
<source/>Psychopharmacology
          <year>2014</year>
<volume>231</volume>
<issue>3</issue>
<fpage>511</fpage>
<lpage>519</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-013-3260-0</pub-id>
<pub-id pub-id-type="pmid">24051602</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liem-Moolenaar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zoethout</surname>
<given-names>RWM</given-names>
</name>
<name>
<surname>de Boer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Kam</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Franson</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>van Gerven</surname>
<given-names>JMA</given-names>
</name>
</person-group>
<article-title>The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects</article-title>
<source/>J Psychopharmacol
          <year>2010</year>
<volume>24</volume>
<issue>11</issue>
<fpage>1671</fpage>
<lpage>1679</lpage>
<pub-id pub-id-type="doi">10.1177/0269881109106942</pub-id>
<pub-id pub-id-type="pmid">20142308</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimazaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kaku</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chaki</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>D-serine and a glycine transporter-1 inhibitor enhance social memory in rats</article-title>
<source/>Psychopharmacology
          <year>2010</year>
<volume>209</volume>
<issue>3</issue>
<fpage>263</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-010-1794-y</pub-id>
<pub-id pub-id-type="pmid">20198471</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Assini</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Duzzioni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>RN</given-names>
</name>
</person-group>
<article-title>Object location memory in mice: Pharmacological validation and further evidence of hippocampal CA1 participation</article-title>
<source/>Behav Brain Res
          <year>2009</year>
<volume>204</volume>
<issue>1</issue>
<fpage>206</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2009.06.005</pub-id>
<pub-id pub-id-type="pmid">19523494</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kumeji</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ichitani</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>D-Cycloserine enhances spatial memory in spontaneous place recognition in rats</article-title>
<source/>Neurosci Lett
          <year>2012</year>
<volume>509</volume>
<issue>1</issue>
<fpage>13</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2011.12.031</pub-id>
<pub-id pub-id-type="pmid">22215115</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bado</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Madeira</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vargas-Lopes</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Moulin</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Wasilewska-Sampaio</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Maretti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>RV</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>OB</given-names>
</name>
<name>
<surname>Panizzutti</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Effects of low-dose D-serine on recognition and working memory in mice</article-title>
<source/>Psychopharmacology
          <year>2011</year>
<volume>218</volume>
<issue>3</issue>
<fpage>461</fpage>
<lpage>470</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-011-2330-4</pub-id>
<pub-id pub-id-type="pmid">21556803</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shimazaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Karasawa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kaku</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Iijima</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kambe</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kawakita</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Okubo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sekiguchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Okuyama</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia</article-title>
<source/>Psychopharmacology
          <year>2015</year>
<volume>232</volume>
<issue>15</issue>
<fpage>2849</fpage>
<lpage>2861</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-015-3920-3</pub-id>
<pub-id pub-id-type="pmid">25869273</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karasawa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chaki</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats</article-title>
<source/>Behav Brain Res
          <year>2008</year>
<volume>186</volume>
<issue>1</issue>
<fpage>78</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2007.07.033</pub-id>
<pub-id pub-id-type="pmid">17854919</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ishima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iyo</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine</article-title>
<source/>Eur Neuropsychopharmacol
          <year>2008</year>
<volume>18</volume>
<issue>6</issue>
<fpage>414</fpage>
<lpage>421</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2007.07.009</pub-id>
<pub-id pub-id-type="pmid">17804206</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Tinker</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Van Velson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giardiniere</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys</article-title>
<source/>Brain Res
          <year>2000</year>
<volume>860</volume>
<issue>1–2</issue>
<fpage>190</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(00)02036-9</pub-id>
<pub-id pub-id-type="pmid">10727642</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuoka</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Aigner</surname>
<given-names>TG</given-names>
</name>
</person-group>
<article-title>D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys</article-title>
<source/>J Pharmacol Exp Ther
          <year>1996</year>
<volume>278</volume>
<issue>2</issue>
<fpage>891</fpage>
<lpage>897</lpage>
<pub-id pub-id-type="pmid">8768744</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajagopal</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Burgdorf</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Moskal</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>HY</given-names>
</name>
</person-group>
<article-title>GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice</article-title>
<source/>Behav Brain Res
          <year>2016</year>
<volume>299</volume>
<fpage>105</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2015.10.060</pub-id>
<pub-id pub-id-type="pmid">26632337</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Agid</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Brune</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bullmore</surname>
<given-names>ET</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Clayton</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Connor</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Deakin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>DeRubeis</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Geyer</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Goodwin</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Gorwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jay</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Joels</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mansuy</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Meyer-Lindenberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rolls</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Saletu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Spedding</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sweeney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Whittington</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>LJ</given-names>
</name>
</person-group>
<article-title>Cognitive dysfunction in psychiatric disorders: Characteristics, causes and the quest for improved therapy</article-title>
<source/>Nat Rev Drug Discov
          <year>2012</year>
<volume>11</volume>
<issue>2</issue>
<fpage>141</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.1038/nrd3628</pub-id>
<pub-id pub-id-type="pmid">22293568</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Portero-Tresserra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cristobal-Narvaez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Marti-Nicolovius</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guillazo-Blanch</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vale-Martinez</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>D-cycloserine in prelimbic cortex reverses scopolamine-induced deficits in olfactory memory in rats</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<issue>8</issue>
<fpage>e70584</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0070584</pub-id>
<pub-id pub-id-type="pmid">23936452</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeVito</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Balu</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Kanter</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Lykken</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Basu</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Coyle</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Eichenbaum</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology</article-title>
<source/>Genes Brain Behav
          <year>2011</year>
<volume>10</volume>
<issue>2</issue>
<fpage>210</fpage>
<lpage>222</lpage>
<pub-id pub-id-type="doi">10.1111/j.1601-183X.2010.00656.x</pub-id>
<pub-id pub-id-type="pmid">21029376</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabricius</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Helboe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fink-Jensen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wortwein</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Steiniger-Brach</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sotty</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Increased dopaminergic activity in socially isolated rats: An electrophysiological study</article-title>
<source/>Neurosci Lett
          <year>2010</year>
<volume>482</volume>
<issue>2</issue>
<fpage>117</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2010.07.014</pub-id>
<pub-id pub-id-type="pmid">20637831</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabricius</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Helboe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fink-Jensen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wortwein</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Steiniger-Brach</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Pharmacological characterization of social isolation-induced hyperactivity</article-title>
<source/>Psychopharmacology (Berl)
          <year>2010</year>
<volume>215</volume>
<issue>2</issue>
<fpage>257</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-010-2128-9</pub-id>
<pub-id pub-id-type="pmid">21193984</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stromme Johannesen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Myhrer</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Impaired visual memory in rats reared in isolation is reversed by D-cycloserine in the adult rat</article-title>
<source/>Eur J Pharmacol
          <year>2002</year>
<volume>437</volume>
<issue>1–2</issue>
<fpage>73</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-2999(02)01282-7</pub-id>
<pub-id pub-id-type="pmid">11864642</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hutson</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>CNS target identification and validation: Avoiding the valley of death or naive optimism?</article-title>
<source/>Annu Rev Pharmacol Toxicol
          <year>2017</year>
<volume>57</volume>
<fpage>171</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010716-104624</pub-id>
<pub-id pub-id-type="pmid">27575715</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goetghebeur</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Swartz</surname>
<given-names>JE</given-names>
</name>
</person-group>
<article-title>True alignment of preclinical and clinical research to enhance success in CNS drug development: A review of the current evidence</article-title>
<source/>J Psychopharmacol
          <year>2016</year>
<volume>30</volume>
<issue>7</issue>
<fpage>586</fpage>
<lpage>594</lpage>
<pub-id pub-id-type="doi">10.1177/0269881116645269</pub-id>
<pub-id pub-id-type="pmid">27147593</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quartermain</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mower</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rafferty</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Herting</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Lanthorn</surname>
<given-names>TH</given-names>
</name>
</person-group>
<article-title>Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention</article-title>
<source/>Eur J Pharmacol
          <year>1994</year>
<volume>257</volume>
<issue>1–2</issue>
<fpage>7</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/0014-2999(94)90687-4</pub-id>
<pub-id pub-id-type="pmid">8082709</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>YQ</given-names>
</name>
<name>
<surname>Ju</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kalia</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Ahmadian</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Salter</surname>
<given-names>MW</given-names>
</name>
</person-group>
<article-title>Glycine binding primes NMDA receptor internalization</article-title>
<source/>Nature
          <year>2003</year>
<volume>422</volume>
<issue>6929</issue>
<fpage>302</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="doi">10.1038/nature01497</pub-id>
<pub-id pub-id-type="pmid">12646920</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buchanan</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Javitt</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Marder</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Schooler</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Gold</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Heresco-Levy</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Carpenter</surname>
<given-names>WT</given-names>
</name>
</person-group>
<article-title>The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments</article-title>
<source/>Am J Psychiatry
          <year>2007</year>
<volume>164</volume>
<issue>10</issue>
<fpage>1593</fpage>
<lpage>1602</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2007.06081358</pub-id>
<pub-id pub-id-type="pmid">17898352</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<mixed-citation publication-type="other">Shimizu S, Sogabe S, Yanagisako R, Inada A, Yamanaka M, Iha HA, Ohno Y (2017) Glycine-binding site stimulants of NMDA receptors alleviate extrapyramidal motor disorders by activating the nigrostriatal dopaminergic pathway. Int J Mol Sci 18(7). 10.3390/ijms18071416</mixed-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>HY</given-names>
</name>
</person-group>
<article-title>Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial</article-title>
<source/>Biol Psychiatry
          <year>2018</year>
<volume>84</volume>
<issue>6</issue>
<fpage>422</fpage>
<lpage>432</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2017.12.006</pub-id>
<pub-id pub-id-type="pmid">29397899</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacobs</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Castellano-Gonzalez</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Lovejoy</surname>
<given-names>DB</given-names>
</name>
</person-group>
<article-title>Major developments in the Design of Inhibitors along the Kynurenine pathway</article-title>
<source/>Curr Med Chem
          <year>2017</year>
<volume>24</volume>
<issue>23</issue>
<fpage>2471</fpage>
<lpage>2495</lpage>
<pub-id pub-id-type="doi">10.2174/0929867324666170502123114</pub-id>
<pub-id pub-id-type="pmid">28464785</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bortz</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>HQ</given-names>
</name>
<name>
<surname>Schwarcz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Oral administration of a specific kynurenic acid synthesis (KAT II) inhibitor attenuates evoked glutamate release in rat prefrontal cortex</article-title>
<source/>Neuropharmacology
          <year>2017</year>
<volume>121</volume>
<fpage>69</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.04.023</pub-id>
<pub-id pub-id-type="pmid">28419874</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishiwata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ogata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Umino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shiraku</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ohashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kajii</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Increasing effects of S-methyl-L-cysteine on the extracellular D-serine concentrations in the rat medial frontal cortex</article-title>
<source/>Amino Acids
          <year>2013</year>
<volume>44</volume>
<issue>5</issue>
<fpage>1391</fpage>
<lpage>1395</lpage>
<pub-id pub-id-type="doi">10.1007/s00726-013-1464-6</pub-id>
<pub-id pub-id-type="pmid">23417484</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Hunihan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Prack</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Harden</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dzierba</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Gentles</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Hendricson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Macor</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Westphal</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>In vitro characterization of a small molecule inhibitor of the alanine serine cysteine transporter −1 (SLC7A10)</article-title>
<source/>J Neurochem
          <year>2014</year>
<volume>129</volume>
<issue>2</issue>
<fpage>275</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.12618</pub-id>
<pub-id pub-id-type="pmid">24266811</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guercio</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Panizzutti</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Potential and challenges for the clinical use of d-serine as a cognitive enhancer</article-title>
<source/>Front Psychiatry
          <year>2018</year>
<volume>9</volume>
<fpage>14</fpage>
<pub-id pub-id-type="doi">10.3389/fpsyt.2018.00014</pub-id>
<pub-id pub-id-type="pmid">29459833</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madeira</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lourenco</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Vargas-Lopes</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Suemoto</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Brandao</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Reis</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Leite</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Laks</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jacob-Filho</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pasqualucci</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Grinberg</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Panizzutti</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>d-serine levels in Alzheimer’s disease: Implications for novel biomarker development</article-title>
<source/>Transl Psychiatry
          <year>2015</year>
<volume>5</volume>
<fpage>e561</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2015.52</pub-id>
<pub-id pub-id-type="pmid">25942042</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Billard</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Serine racemase as a prime target for age-related memory deficits</article-title>
<source/>Eur J Neurosci
          <year>2013</year>
<volume>37</volume>
<issue>12</issue>
<fpage>1931</fpage>
<lpage>1938</lpage>
<pub-id pub-id-type="doi">10.1111/ejn.12226</pub-id>
<pub-id pub-id-type="pmid">23773062</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>HY</given-names>
</name>
</person-group>
<article-title>Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>14849</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-13951-7</pub-id>
<pub-id pub-id-type="pmid">29093468</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Modi</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>LJ</given-names>
</name>
</person-group>
<article-title>D-cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders</article-title>
<source/>Biol Psychiatry
          <year>2011</year>
<volume>70</volume>
<issue>3</issue>
<fpage>298</fpage>
<lpage>304</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2011.01.026</pub-id>
<pub-id pub-id-type="pmid">21481844</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Na</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>De Jesus-Cortes</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Martinez-Rivera</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kabir</surname>
<given-names>ZD</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ramesh</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Onder</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Rajadhyaksha</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Monteggia</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Pieper</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>D-cycloserine improves synaptic transmission in an animal model of Rett syndrome</article-title>
<source/>PLoS One
          <year>2017</year>
<volume>12</volume>
<issue>8</issue>
<fpage>e0183026</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0183026</pub-id>
<pub-id pub-id-type="pmid">28813484</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Price</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>McRae-Clark</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Saladin</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Desantis</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Santa Ana</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>KT</given-names>
</name>
</person-group>
<article-title>A randomized, placebo-controlled laboratory study of the effects of D-cycloserine on craving in cocaine-dependent individuals</article-title>
<source/>Psychopharmacology
          <year>2013</year>
<volume>226</volume>
<issue>4</issue>
<fpage>739</fpage>
<lpage>746</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-011-2592-x</pub-id>
<pub-id pub-id-type="pmid">22234379</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armbruster</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kotter</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hermanns</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Werdehausen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Eulenburg</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>The GlyT1 inhibitor bitopertin ameliorates allodynia and hyperalgesia in animal models of neuropathic and inflammatory pain</article-title>
<source/>Front Mol Neurosci
          <year>2017</year>
<volume>10</volume>
<fpage>438</fpage>
<pub-id pub-id-type="doi">10.3389/fnmol.2017.00438</pub-id>
<pub-id pub-id-type="pmid">29375301</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Otto</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Kredlow</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>JAJ</given-names>
</name>
<name>
<surname>Hofmann</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Tolin</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>de Kleine</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>van Minnen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Evins</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Pollack</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Enhancement of psychosocial treatment with D-cycloserine: Models, moderators, and future directions</article-title>
<source/>Biol Psychiatry
          <year>2016</year>
<volume>80</volume>
<issue>4</issue>
<fpage>274</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2015.09.007</pub-id>
<pub-id pub-id-type="pmid">26520240</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>